var title_f42_54_43872="PCMZL multifocal skin lesions";
var content_f42_54_43872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous marginal zone lymphoma multifocal skin lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43872=[""].join("\n");
var outline_f42_54_43872=null;
var title_f42_54_43873="Lateral knee anatomy adult";
var content_f42_54_43873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Lateral anatomy of the knee",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 522px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43873=[""].join("\n");
var outline_f42_54_43873=null;
var title_f42_54_43874="Hyperacute rejection Light";
var content_f42_54_43874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal allograft biopsy showing hyperacute rejection by light microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a glomerulus in hyperacute rejection. There is a thrombus in the afferent arteriole (arrow) and there is extensive necrosis of the glomerular tuft (which has few cells) and the surrounding parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43874=[""].join("\n");
var outline_f42_54_43874=null;
var title_f42_54_43875="Color Doppler imaging of aortic dissection";
var content_f42_54_43875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82646%7ECARD%2F69102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82646%7ECARD%2F69102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color Doppler imaging of aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color flow mapping of type B dissection of the descending thoracic aorta using transesophageal echocardiography (0&deg; crystal orientation). There are differences in blood flow velocity on both sides of the intimal flap: the red color indicates blood flow in the true lumen (TL), while the lack of color indicates little or no flow in the false lumen (FL). The true and false lumen are defined by the respective presence or absence of an endothelial lining. The true lumen is best identified by imaging the proximal border of the dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD and Roberto Lang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color flow mapping of aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color flow mapping of type B dissection of the descending thoracic aorta using transesophageal echocardiography (0&deg; crystal orientation). The red and blue color indicates blood flow in the true lumen, while the lack of color indicates little or no flow in the surrounding false lumen (FL).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43875=[""].join("\n");
var outline_f42_54_43875=null;
var title_f42_54_43876="Methsuximide: Drug information";
var content_f42_54_43876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methsuximide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/29/15829?source=see_link\">",
"    see \"Methsuximide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/58/10149?source=see_link\">",
"    see \"Methsuximide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Celontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Celontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F194874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Succinimide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F194865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Anticonvulsant:",
"     </b>",
"     Oral: 300 mg/day for the first week; may increase by 300 mg/day at weekly intervals up to 1.2 g/day in 2-4 divided doses/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F194866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Celontin&reg;: 150 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10916633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229201.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229201.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F194847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control of absence (petit mal) seizures that are refractory to other drugs",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F194871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Partial complex (psychomotor) seizures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methsuximide may be confused with ethosuximide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F194872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hyperemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggressiveness, ataxia, confusion, depression, dizziness, drowsiness, hallucinations (auditory), headache, hypochondriacal behavior, insomnia, irritability, mental instability, mental slowness, nervousness, psychosis, suicidal behavior",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, Stevens-Johnson syndrome, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, epigastric pain, nausea, vomiting, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria (microscopic), proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, leukopenia, monocytosis, pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, periorbital edema, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hiccups, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F194851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of hypersensitivity to succinimides",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F194835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Succinimides have been associated with severe blood dyscrasias (sometimes fatal). Monitor blood counts periodically, especially if signs/symptoms of infection develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Succinimides have been associated with cases of systemic lupus erythematosus (SLE).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Must be used in combination with other anticonvulsants in patients with both absence and tonic-clonic seizures. May increase tonic-clonic seizures when used alone in patients with mixed seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F194869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7793124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     Patients exposed to methsuximide during pregnancy are encouraged to enroll themselves into the NAAED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F194853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Celontin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $228.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F194844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, hepatic function tests, urinalysis; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F7983783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: N-desmethylmethsuximide: 20-40 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F194834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the seizure threshold and suppresses paroxysmal spike-and-wave pattern in absence seizures; depresses nerve transmission in the motor cortex",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F194850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; rapidly demethylated to N-desmethylmethsuximide (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Within 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Miles MV, Tennison MB, and Greenwood RS, &ldquo;Pharmacokinetics of N-desmethylmethsuximide in Pediatric Patients,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(4 Pt 1):647-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/54/43876/abstract-text/2926578/pubmed\" id=\"2926578\" target=\"_blank\">",
"        2926578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tennison MB, Greenwood RS, Miles MV, &ldquo;Methsuximide for Intractable Childhood Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1991, 87(2):186-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/54/43876/abstract-text/1987529/pubmed\" id=\"1987529\" target=\"_blank\">",
"        1987529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9632 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43876=[""].join("\n");
var outline_f42_54_43876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194874\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194865\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194866\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194846\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194831\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10916633\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194847\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194871\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194878\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194872\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194851\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194835\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194869\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194839\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7793124\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194853\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194844\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7983783\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194834\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194850\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9632|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/29/15829?source=related_link\">",
"      Methsuximide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/58/10149?source=related_link\">",
"      Methsuximide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_54_43877="Breast clustered cysts mammogram and ultrasound";
var content_f42_54_43877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Breast clustered cysts mammogram and ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mammogram of the right breast using LMLO projection (A) and LCC projection (B) shows a small soft tissue mass (yellow rings). The&nbsp;ultrasound of the mass shows a cluster of grape like anechoic structures with some internal septations (red arrow) in the longitudinal view (C) and in the transverse view (D). These findings are consistent with a diagnosis of septated cyst.",
"    <div class=\"footnotes\">",
"     LMLO: left mediolateral oblique; LCC: left craniocaudal.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Priscilla J Slanetz, MD, MPH, FACR.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43877=[""].join("\n");
var outline_f42_54_43877=null;
var title_f42_54_43878="Gram stain sputum 4A answer";
var content_f42_54_43878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58744%7EID%2F59330%7EID%2F72828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58744%7EID%2F59330%7EID%2F72828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Haemophilus influenzae in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows inflammatory cells and very small, Gram negative coccobacilli. Haemophilus influenzae grew from this specimen on chocolate agar and was shown to utilize X and V factors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Haemophilus influenzae on chocolate agar plate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Haemophilus influenzae does not grow on a sheep blood agar plate, but does produce small, translucent colonies on chocolate agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Test for utilization of X and V factors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On brain heart infusion agar, which lacks both X and V factors, Haemophilus influenzae grows only where both factors have diffused between the paper strips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43878=[""].join("\n");
var outline_f42_54_43878=null;
var title_f42_54_43879="Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis";
var content_f42_54_43879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43879/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43879/contributors\">",
"     E Dale Everett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43879/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43879/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43879/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43879/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/54/43879/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptospirosis is a zoonosis with protean manifestations caused by the spirochete, Leptospira interrogans. Synonyms for the disease include Weil's disease, Swineherd's disease, rice-field fever, cane-cutter fever, swamp fever, mud fever, hemorrhagic jaundice, Stuttgart disease, and Canicola fever.",
"   </p>",
"   <p>",
"    The microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis will be presented here. The treatment and prevention of this disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4597?source=see_link\">",
"     \"Treatment and prevention of leptospirosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genus Leptospira consists of two species, L. interrogans and L. biflexia, only the former of which is known to cause human disease. More than 200 serovars of L. interrogans have been identified. Leptospira are spiral-shaped aerobic spirochetes with 18 or more coils per cell. They tend to stain poorly with common laboratory stains and are best visualized by dark field microscopy, silver stain or fluorescent microscopy.",
"   </p>",
"   <p>",
"    Unlike the clinically important spirochete Treponema pallidum, L. interrogans can be grown in vitro from clinical specimens including blood, urine, and cerebrospinal fluid (CSF). Special media are required for isolation such as Fletcher's, Ellinghausen's, or polysorbate 80 media. Therefore, the laboratory needs to be notified if an attempt to isolate leptospira is desired. Growth is usually observed in one to two weeks but may take up to three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whole genome-sequencing of a representative virulent strain of L. interrogans has identified a series of genes possibly related to adhesion, invasion, and the hematological changes that characterize leptospirosis, allowing in depth studies of virulence and pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of leptospirosis cases occur in the tropics, although cases are also observed in temperate regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/3\">",
"     3",
"    </a>",
"    ]. The natural hosts for the organism are various mammals; man is only incidentally infected, typically after exposure to the environment contaminated by animal urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Animal infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The organism infects a variety of both wild and domestic mammals, especially rodents, cattle, swine, dogs, horses, sheep, and goats. The disease rarely occurs in cats. Animals can be asymptomatic or develop clinical infection, which can be fatal. Mortality in dogs is estimated at approximately 10 percent. Spontaneous abortion is a common outcome of leptospirosis in cattle, swine, sheep, and goats.",
"   </p>",
"   <p>",
"    Infection in small rodents (carrier animals) usually occurs during infancy, and once infected, animals may shed the organism in their urine intermittently or continuously throughout life resulting in contamination of the environment, particularly water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/4\">",
"     4",
"    </a>",
"    ]. Organisms may remain viable for days to months in soil and water with a neutral pH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Human infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, most cases are reported from the southern and Pacific coastal states. Hawaii consistently reports the most cases of any state. Leptospirosis has also been described in Florida [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/5\">",
"     5",
"    </a>",
"    ] and Puerto Rico [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worldwide, endemic disease occurs in the tropics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The magnitude of disease in tropical countries was illustrated in a prospective, hospital-based and population-based study of acute fever in Iquitos, Peru [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/10\">",
"     10",
"    </a>",
"    ]. Between June 2003 and March 2004, 633 febrile patients were evaluated; 321 (51 percent) had serologic evidence of acute leptospirosis.",
"   </p>",
"   <p>",
"    The incidence of leptospirosis in some endemic countries appears to be increasing. In Thailand, for example, the reported incidence increased 30-fold between 1995 and 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/11\">",
"     11",
"    </a>",
"    ]. The reason for the increase is unknown, however, hypotheses include an increase in the rat population and seasonal flooding.",
"   </p>",
"   <p>",
"    The importance of exposure to contaminated water is illustrated by two outbreaks, one in Taiwan was observed during the flooding from a typhoon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/12\">",
"     12",
"    </a>",
"    ]; a second outbreak occurred in India following exposure to infected water in a canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Humans most often become infected after exposure to environmental sources, such as animal urine, contaminated water or soil, or infected animal tissue. Portals of entry include cuts or abraded skin, mucous membranes or conjunctiva. The infection is rarely acquired by ingestion of food contaminated with urine or via aerosols. Controversy exists as to whether Leptospira can penetrate the intact skin.",
"   </p>",
"   <p>",
"    While disease in humans is often sporadic, outbreaks may occur from common source exposures. Participation in a triathlon where the swimming portion was in fresh water has been responsible for outbreaks of leptospirosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An outbreak occurred in 98 of 834 (12 percent) athletes participating in an Illinois triathlon, probably after exposure to lake water in the swimming phase of the event. Serum samples obtained from 474 athletes were tested; 52 (11 percent) had a positive enzyme linked immunosorbent assay (ELISA) test for the organism in acute serum and met the Centers for Disease Control and Prevention (CDC) clinical case definition for leptospirosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another outbreak among swimmers occurred in Borneo, Malaysia in the year 2000; 44 percent of 158 athletes contacted met the case definition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/15\">",
"       15",
"      </a>",
"      ]. Swimming in the Segama River was associated with a 38 percent attributable risk of acquiring leptospirosis, which was endemic in the area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since travelers more commonly participate in recreational activities, the risk of developing this infection has increased, necessitating awareness of physicians caring for these patients upon their return.",
"   </p>",
"   <p>",
"    Risk factors for infection include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational exposure &mdash; farmers, ranchers, abattoir workers, trappers, veterinarians, loggers, sewer workers, rice field workers, military personnel, laboratory workers",
"     </li>",
"     <li>",
"      Recreational activities &mdash; fresh water swimming, canoeing, kayaking, trail biking",
"     </li>",
"     <li>",
"      Household exposure &mdash; pet dogs, domesticated livestock, rainwater catchment systems, and infestation by infected rodents.",
"     </li>",
"     <li>",
"      Other &mdash; Skin lesions, contact with wild rodents",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptospirosis is associated with a variable clinical course. The disease may manifest as a subclinical illness followed by seroconversion, a self-limited systemic infection, or a severe, potentially fatal illness accompanied by multiorgan failure.",
"   </p>",
"   <p>",
"    Leptospirosis presents with the abrupt onset of fever, rigors, myalgias and headache in 75 to 100 percent of patients, after an incubation period of two to 26 days (average 10 days). From 25 to 35 percent of cases have an associated nonproductive cough and approximately 50 percent experience nausea, vomiting and diarrhea. Other less common symptoms include arthralgias, bone pain, sore throat, and abdominal pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/9,19\">",
"     9,19",
"    </a>",
"    ]; acalculous cholecystitis can occur in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/20\">",
"     20",
"    </a>",
"    ]. While leptospirosis has classically been described as a biphasic illness, fewer than 50 percent of cases exhibit a biphasic course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination is often unrevealing. An important, but frequently overlooked sign, is conjunctival suffusion. This is not a common finding in other infectious diseases, and its presence in a patient with a nonspecific febrile illness should raise the diagnosis of leptospirosis. From 7 to 40 percent of patients can have muscle tenderness, splenomegaly, lymphadenopathy, pharyngitis, hepatomegaly, muscle rigidity, abnormal respiratory auscultation, or skin rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Aseptic meningitis can be documented in 50 to 85 percent of patients if cerebrospinal fluid (CSF) is examined after seven days of illness. The meningitis is thought to be secondary to a host immune response to the organism rather than to direct infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case-control study in Taiwan during an outbreak of leptospirosis in adults identified the following clinical and laboratory findings associated with serologically confirmed cases compared to excluded cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhagic diathesis (odds ratio [OR], 10; 95% CI, 1.1-90.8)",
"     </li>",
"     <li>",
"      Myalgia (OR, 8.0; 95% CI, 1.4-45.8)",
"     </li>",
"     <li>",
"      Bilateral enlarged kidneys (OR, 7.5; 95% CI, 2.5-22.7)",
"     </li>",
"     <li>",
"      Sterile pyuria (OR, 6.3; 95% CI, 1.4-27.8)",
"     </li>",
"     <li>",
"      Hypokalemia (OR, 5.0; 95% CI, 1.1-22.3)",
"     </li>",
"     <li>",
"      Thrombocytopenia (OR, 4.8; 95% CI, 1.1-21.1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Leptospirosa has the capacity to act directly on electrolyte transport mechanisms, thereby inducing derangements of sodium and potassium. Studies indicate that an outer membrane protein of leptospira inhibits the Na+-K+-Cl- co-transporter activity in the thick ascending limb of Henle, resulting in hypokalemia and sodium wasting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During an outbreak of leptospirosis in India, 90 children with suspected leptospirosis were screened with serologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/25\">",
"     25",
"    </a>",
"    ]. Fifteen (17 percent) had leptospirosis. Clinical features that were significantly associated with leptospirosis included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conjunctival suffusion",
"     </li>",
"     <li>",
"      Hemorrhage",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      Hepatosplenomegaly",
"     </li>",
"     <li>",
"      Edema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are few reported cases of leptospirosis in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. When the disease does occur, the clinical manifestations in HIV-infected patients are similar to those in immunocompetent patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most cases of leptospirosis are mild to moderate, the course may be complicated by renal failure, uveitis, hemorrhage, acute respiratory distress syndrome, myocarditis and rhabdomyolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Liver failure is generally reversible and not a cause of death in leptospirosis. Dyspnea, oliguria, WBC counts above",
"    <span class=\"nowrap\">",
"     12,900/mm3,",
"    </span>",
"    repolarization abnormalities on electrocardiograms, and alveolar infiltrates on chest radiography have been associated with adverse outcomes. Vasculitis with necrosis of extremities may be seen in severe cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential severity of leptospirosis was illustrated in a retrospective study of 60 patients with leptospirosis requiring ICU admission in India [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/32\">",
"     32",
"    </a>",
"    ]. Multiorgan failure developed in 46 patients (77 percent); the mortality for patients with leptospirosis requiring ICU admission was 52 percent.",
"   </p>",
"   <p>",
"    Severe pulmonary disease may be underdiagnosed in regions of high endemicity. Among 321 patients with serologic and clinical evidence of leptospirosis in Peru, seven (3.7 percent) had severe pulmonary manifestations, including hemoptysis in six [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/10\">",
"     10",
"    </a>",
"    ]. Five of the seven patients died, four from pulmonary hemorrhage and one from acute respiratory distress syndrome and multiorgan failure. The authors noted that a diagnosis of leptospirosis would have been missed in patients with fever and hemoptysis by local physicians if they had not been part of the fever study, which included serology, culture, and PCR for leptospirosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptospirosis is a nonspecific clinical illness, and routine laboratory tests are similarly nondiagnostic. White blood cell (WBC) counts are generally less than",
"    <span class=\"nowrap\">",
"     10,000/mm3",
"    </span>",
"    but may range between 3,000 and",
"    <span class=\"nowrap\">",
"     26,000/microL;",
"    </span>",
"    a shift to the left is seen in about two-thirds of patients. Urinalysis frequently shows proteinuria, pyuria, granular casts and occasionally microscopic hematuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/22\">",
"     22",
"    </a>",
"    ]. Elevated creatine kinase is found in approximately 50 percent of patients and may be a useful clue for the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/33\">",
"     33",
"    </a>",
"    ]. Approximately 40 percent of patients have minimal to moderate elevations of hepatic transaminases (usually &lt;200",
"    <span class=\"nowrap\">",
"     IU/L).",
"    </span>",
"    Hyponatremia is common in severe leptospirosis.",
"   </p>",
"   <p>",
"    Jaundice is only observed in patients with Weil's syndrome, the most severe form of leptospirosis. Patients with this syndrome can develop hepatic and renal dysfunction and hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/16\">",
"     16",
"    </a>",
"    ]. In occasional patients, the serum bilirubin concentration reaches 60 to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1026 to 1368",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Thrombocytopenia is uncommon, but a poorly understood hemorrhagic diathesis may occur in the absence of demonstrable coagulation defects or severe thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/34\">",
"     34",
"    </a>",
"    ]. Pancytopenia has been reported as the presenting manifestation in case reports with complete resolution following treatment with penicillin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/35\">",
"     35",
"    </a>",
"    ]. The CSF may show a neutrophilic or lymphocytic pleocytosis with minimal to moderately elevated protein concentrations and normal glucose. A low CSF glucose concentration is rarely seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs may show small nodular densities, which can progress to confluent consolidation or a ground glass appearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/37\">",
"     37",
"    </a>",
"    ]. Pathologically, these infiltrates may represent alveolar hemorrhage, ARDS, or pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptospirosis may be confused with a number of different infectious illnesses. Conjunctival suffusion, when it occurs, is one of the most reliable distinguishing features since it rarely occurs with any infectious illness other than leptospirosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malaria and dengue share some common clinical features and similar endemic patterns with leptospirosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5543?source=see_link\">",
"       \"Clinical manifestations of malaria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18985?source=see_link\">",
"       \"Clinical presentation and diagnosis of dengue virus infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Scrub typhus is a common disease in some tropical regions where leptospirosis also occurs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18534?source=see_link\">",
"       \"Scrub typhus: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other rickettsial disease, such as infections with spotted fever group of rickettsiae may mimic leptospirosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28808?source=see_link\">",
"       \"Other spotted fever group rickettsial infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leptospirosis may mimic infection with Salmonella typhi in areas of the tropics where typhoid fever is common, particularly in patients with prominent gastrointestinal complaints. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42024?source=see_link\">",
"       \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ehrlichiosis may present with similar clinical manifestations including fever and nonspecific complaints. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=see_link\">",
"       \"Human ehrlichiosis and anaplasmosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute viral illnesses including influenza may mimic leptospirosis, particularly in patients with prominent respiratory tract symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"       \"Clinical manifestations of seasonal influenza in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hantavirus can cause a renal syndrome similar to the renal disease observed in leptospirosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25544?source=see_link\">",
"       \"Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adenovirus can cause conjunctival suffusion and multi-organ system illness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"       \"Epidemiology and clinical manifestations of adenovirus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the clinical features and routine laboratory findings of leptospirosis are not specific, a high index of suspicion must be maintained for the diagnosis. The organism can be cultured, but the diagnosis is more frequently made by serologic testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, leptospirosis can be confirmed by culture of the organism from clinical specimens in appropriate media. Blood and CSF specimens are positive during the first 10 days of the illness. Isolation of the organism from the blood is successful in approximately 50 percent of cases. Urine cultures become positive during the second week of the illness and remain so for up to 30 days after the resolution of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because some clinical microbiology laboratories do not offer culture for the diagnosis of leptospirosis, serological tests are most often used for confirmation. A number of serologic tests are employed or are under development, including the microscopic agglutination test (MAT), macroscopic agglutination test, indirect hemagglutination, and ELISA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While all of these assays are useful in establishing the diagnosis, the gold standard is considered to be the MAT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/37\">",
"     37",
"    </a>",
"    ]. Unfortunately, this test requires live organisms, considerable expertise, and is performed only by reference laboratories such as the CDC. Like other serologic tests, the MAT is most specific when a fourfold or greater rise in titer is detected between acute and convalescent serum specimens. However, a single titer of &gt;1:800 is strong evidence of current or recent infection with leptospira. Cross reactive antibodies have been associated with syphilis, relapsing fever, Lyme disease, and legionellosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/1\">",
"     1",
"    </a>",
"    ]. The level of the antibody titers as found in the MAT cannot be used to predict the serovar that infects the individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the MAT is not readily available, another assay typically is performed first in suspected cases of leptospirosis. Two commercially available rapid tests, the microplate IgM ELISA and an IgM dot-ELISA dipstick test, performed well in studies conducted in the United States and Thailand that used MAT as the comparator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. If one of these assays is positive, sera for MAT can then be sent to the CDC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Molecular techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular techniques, such as polymerase chain reaction (PCR), are being explored to assist in the diagnosis of leptospirosis. These techniques are not widely available but are promise tools for quick, accurate diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43879/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/40/37505?source=see_link\">",
"       \"Patient information: Leptospirosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leptospirosis is a zoonosis with protean manifestations caused by the spirochete, Leptospira interrogans. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leptospirosis is distributed worldwide, however, the majority of clinical cases occur in the tropics. In the United States, Hawaii consistently reports the most cases. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The organism infects a variety of both wild and domestic mammals, especially rodents, cattle, swine, dogs, horses, sheep, and goats. Animals can be asymptomatic or develop clinical infection, which can be fatal. Animals may shed the organism in their urine intermittently or continuously throughout life resulting in contamination of the environment, particularly water. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Animal infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Humans most often become infected after exposure to environmental sources, such as animal urine, contaminated water or soil, or infected animal tissue through cuts or abraded skin, mucous membranes or conjunctiva. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Human infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leptospirosis is associated with a variable clinical course. The disease may manifest as a subclinical illness followed by seroconversion, a self-limited systemic infection, or a severe, potentially fatal illness accompanied by multiorgan failure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leptospirosis presents with the abrupt onset of fever, rigors, myalgias and headache in 75 to 100 percent of patients. While leptospirosis has classically been described as a biphasic illness, fewer than 50 percent of cases exhibit a biphasic course. Conjunctival suffusion in a patient with a nonspecific febrile illness should raise suspicion for the diagnosis of leptospirosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While most cases of leptospirosis are mild to moderate, the course may be complicated by renal failure, uveitis, hemorrhage, acute respiratory distress syndrome, myocarditis and rhabdomyolysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because the clinical features and routine laboratory findings of leptospirosis are not specific, a high index of suspicion must be maintained for the diagnosis. The organism can be cultured, but the diagnosis is more frequently made by serologic testing. The microscopic agglutination test (MAT) is considered the gold standard for serologic diagnosis, but requires expertise that is not available in most laboratories; it can be obtained through the CDC in the United States. Rapid serologic tests have been developed that have performed well in clinical studies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kaufmann, AF, Weyant, RS. Leptospiraceae. In: Manual of Clinical Microbiology, 6th ed, ASM Press, Washington, DC, 1995, p. 621.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/2\">",
"      Ren SX, Fu G, Jiang XG, et al. Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing. Nature 2003; 422:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/3\">",
"      Desai S, van Treeck U, Lierz M, et al. Resurgence of field fever in a temperate country: an epidemic of leptospirosis among seasonal strawberry harvesters in Germany in 2007. Clin Infect Dis 2009; 48:691.",
"     </a>",
"    </li>",
"    <li>",
"     Acha, PN, Szyfres, B. Leptospirosis. In: Zoonoses and Communicable Disease Common to Man and Animals, 3rd Pan American Health Organization, Washington, DC, 2001, p. 157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/5\">",
"      Stern EJ, Galloway R, Shadomy SV, et al. Outbreak of leptospirosis among Adventure Race participants in Florida, 2005. Clin Infect Dis 2010; 50:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: investigation of leptospirosis underreporting - Puerto Rico, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/7\">",
"      Bovet P, Yersin C, Merien F, et al. Factors associated with clinical leptospirosis: a population-based case-control study in the Seychelles (Indian Ocean). Int J Epidemiol 1999; 28:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/8\">",
"      Van CT, Thuy NT, San NH, et al. Human leptospirosis in the Mekong delta, Viet Nam. Trans R Soc Trop Med Hyg 1998; 92:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/9\">",
"      Bertherat E, Renaut A, Nabias R, et al. Leptospirosis and Ebola virus infection in five gold-panning villages in northeastern Gabon. Am J Trop Med Hyg 1999; 60:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/10\">",
"      Segura ER, Ganoza CA, Campos K, et al. Clinical spectrum of pulmonary involvement in leptospirosis in a region of endemicity, with quantification of leptospiral burden. Clin Infect Dis 2005; 40:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/11\">",
"      Sejvar J, Tangkanakul W, Ratanasang P, et al. An outbreak of leptospirosis, Thailand--the importance of the laboratory. Southeast Asian J Trop Med Public Health 2005; 36:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/12\">",
"      Yang HY, Hsu PY, Pan MJ, et al. Clinical distinction and evaluation of leptospirosis in Taiwan--a case-control study. J Nephrol 2005; 18:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/13\">",
"      Jena AB, Mohanty KC, Devadasan N. An outbreak of leptospirosis in Orissa, India: the importance of surveillance. Trop Med Int Health 2004; 9:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/14\">",
"      Morgan J, Bornstein SL, Karpati AM, et al. Outbreak of leptospirosis among triathlon participants and community residents in Springfield, Illinois, 1998. Clin Infect Dis 2002; 34:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Update: outbreak of acute febrile illness among athletes participating in Eco-Challenge-Sabah 2000--Borneo, Malaysia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/16\">",
"      Farr RW. Leptospirosis. Clin Infect Dis 1995; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/17\">",
"      Nardone A, Capek I, Baranton G, et al. Risk factors for leptospirosis in metropolitan France: results of a national case-control study, 1999-2000. Clin Infect Dis 2004; 39:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/18\">",
"      Sugunan AP, Natarajaseenivasan K, Vijayachari P, Sehgal SC. Percutaneous exposure resulting in laboratory-acquired leptospirosis -- a case report. J Med Microbiol 2004; 53:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/19\">",
"      Katz AR, Ansdell VE, Effler PV, et al. Assessment of the clinical presentation and treatment of 353 cases of laboratory-confirmed leptospirosis in Hawaii, 1974-1998. Clin Infect Dis 2001; 33:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/20\">",
"      Wong ML, Kaplan S, Dunkle LM, et al. Leptospirosis: a childhood disease. J Pediatr 1977; 90:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/21\">",
"      Sanford JP. Leptospirosis--time for a booster. N Engl J Med 1984; 310:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/22\">",
"      Berman, SJ, Tsai, C, Holmes, K, et al. Sporadic anicteric leptospirosis in South Vietnam. Ann Intern Med, 1973; 79:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/23\">",
"      Wu MS, Yang CW, Pan MJ, et al. Reduced renal Na+-K+-Cl- co-transporter activity and inhibited NKCC2 mRNA expression by Leptospira shermani: from bed-side to bench. Nephrol Dial Transplant 2004; 19:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/24\">",
"      Krishnan A, Karnad DR, Medhekar TP. Paralysis due to renal potassium wasting: an unusual presentation of leptospirosis. Nephrol Dial Transplant 2003; 18:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/25\">",
"      Karande S, Gandhi D, Kulkarni M, et al. Concurrent outbreak of leptospirosis and dengue in Mumbai, India, 2002. J Trop Pediatr 2005; 51:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/26\">",
"      Ganoza CA, Segura ER, Swancutt MA, et al. Mild, self-resolving acute leptospirosis in an HIV-infected patient in the Peruvian Amazon. Am J Trop Med Hyg 2005; 73:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/27\">",
"      Neves Ede S, Pereira MM, Galhardo MC, et al. Leptospirosis patient with AIDS: the first case reported. Rev Soc Bras Med Trop 1994; 27:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/28\">",
"      Jones S, Kim T. Fulminant leptospirosis in a patient with human immunodeficiency virus infection: case report and review of the literature. Clin Infect Dis 2001; 33:E31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/29\">",
"      Dupont H, Dupont-Perdrizet D, Perie JL, et al. Leptospirosis: prognostic factors associated with mortality. Clin Infect Dis 1997; 25:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/30\">",
"      Rathinam SR, Rathnam S, Selvaraj S, et al. Uveitis associated with an epidemic outbreak of leptospirosis. Am J Ophthalmol 1997; 124:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/31\">",
"      Cetin BD, Harmankaya O, Hasman H, et al. Acute renal failure: a common manifestation of leptospirosis. Ren Fail 2004; 26:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/32\">",
"      Chawla V, Trivedi TH, Yeolekar ME. Epidemic of leptospirosis: an ICU experience. J Assoc Physicians India 2004; 52:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/33\">",
"      Johnson WD Jr, Silva IC, Rocha H. Serum creatine phosphokinase in leptospirosis. JAMA 1975; 233:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/34\">",
"      Chierakul W, Tientadakul P, Suputtamongkol Y, et al. Activation of the coagulation cascade in patients with leptospirosis. Clin Infect Dis 2008; 46:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/35\">",
"      Stefos A, Georgiadou SP, Gioti C, et al. Leptospirosis and pancytopenia: two case reports and review of the literature. J Infect 2005; 51:e277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/36\">",
"      Helmer RE 3rd, Millsaps RD. Letter: Hypoglycorrachia in leptospirosis. Ann Intern Med 1973; 79:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/37\">",
"      Im JG, Yeon KM, Han MC, et al. Leptospirosis of the lung: radiographic findings in 58 patients. AJR Am J Roentgenol 1989; 152:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/38\">",
"      Carvalho CR, Bethlem EP. Pulmonary complications of leptospirosis. Clin Chest Med 2002; 23:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/39\">",
"      Winslow WE, Merry DJ, Pirc ML, Devine PL. Evaluation of a commercial enzyme-linked immunosorbent assay for detection of immunoglobulin M antibody in diagnosis of human leptospiral infection. J Clin Microbiol 1997; 35:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/40\">",
"      Levett PN, Whittington CU. Evaluation of the indirect hemagglutination assay for diagnosis of acute leptospirosis. J Clin Microbiol 1998; 36:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/41\">",
"      Levett PN. Usefulness of serologic analysis as a predictor of the infecting serovar in patients with severe leptospirosis. Clin Infect Dis 2003; 36:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/42\">",
"      Bajani MD, Ashford DA, Bragg SL, et al. Evaluation of four commercially available rapid serologic tests for diagnosis of leptospirosis. J Clin Microbiol 2003; 41:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/43\">",
"      Tansuphasiri U, Deepradit S, Phulsuksombati D, Tangkanakul W. Two simple immunoassays using endemic leptospiral antigens for serodiagnosis of human leptospirosis. Southeast Asian J Trop Med Public Health 2005; 36:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/44\">",
"      Merien F, Portnoi D, Bourhy P, et al. A rapid and quantitative method for the detection of Leptospira species in human leptospirosis. FEMS Microbiol Lett 2005; 249:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/45\">",
"      Zuerner RL, Bolin CA. Differentiation of Leptospira interrogans isolates by IS1500 hybridization and PCR assays. J Clin Microbiol 1997; 35:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/46\">",
"      Woo TH, Patel BK, Smythe LD, et al. Identification of pathogenic Leptospira genospecies by continuous monitoring of fluorogenic hybridization probes during rapid-cycle PCR. J Clin Microbiol 1997; 35:3140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/47\">",
"      Romero EC, Billerbeck AE, Lando VS, et al. Detection of Leptospira DNA in patients with aseptic meningitis by PCR. J Clin Microbiol 1998; 36:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43879/abstract/48\">",
"      Agampodi SB, Matthias MA, Moreno AC, Vinetz JM. Utility of quantitative polymerase chain reaction in leptospirosis diagnosis: association of level of leptospiremia and clinical manifestations in Sri Lanka. Clin Infect Dis 2012; 54:1249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5527 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43879=[""].join("\n");
var outline_f42_54_43879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Animal infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Human infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Molecular techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28808?source=related_link\">",
"      Other spotted fever group rickettsial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/40/37505?source=related_link\">",
"      Patient information: Leptospirosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25544?source=related_link\">",
"      Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/6/18534?source=related_link\">",
"      Scrub typhus: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4597?source=related_link\">",
"      Treatment and prevention of leptospirosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_54_43880="Approach to the child with anemia";
var content_f42_54_43880=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the child with anemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43880/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43880/contributors\">",
"     Claudio Sandoval, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43880/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43880/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43880/contributors\">",
"     Martin I Lorin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43880/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43880/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/54/43880/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to anemia in the pediatric patient is reviewed here. Included are pertinent issues related to the history and physical examination, the initial laboratory workup, methods for classifying anemia, and algorithms designed to help guide diagnosis.",
"   </p>",
"   <p>",
"    A systematic approach to the examination of the peripheral blood smear and bone marrow is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13689?source=see_link\">",
"     \"Evaluation of bone marrow aspirate smears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia may be defined as a reduction in red blood cell (RBC) mass or blood hemoglobin concentration. In practice, anemia most commonly is defined by reductions in one or both of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematocrit (HCT) &mdash; The hematocrit is the fractional volume of a whole blood sample occupied by red blood cells (RBCs), expressed as a percentage. As an example, the normal HCT in a child age 6 to 12 years is approximately 40 percent.",
"     </li>",
"     <li>",
"      Hemoglobin (HGB) &mdash; This is a measure of the concentration of the RBC pigment hemoglobin in whole blood, expressed as grams per 100 mL (dL) of whole blood. The normal value for HGB in a child age 6 to 12 years is approximately 13.5",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The threshold for defining anemia is a HGB or HCT that is more than two standard deviations below the mean for the reference population. Normal ranges for HGB and HCT vary substantially with age; thus, it is particularly important to use age and sex adjusted norms when evaluating a pediatric patient for anemia (",
"    <a class=\"graphic graphic_table graphicRef57465 \" href=\"mobipreview.htm?5/34/5679\">",
"     table 1",
"    </a>",
"    ). In addition, there is racial variation, with healthy black children having average hemoglobin values 0.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    below that of white children of the same age and sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF ERYTHROPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal erythropoiesis begins with primitive megaloblastic erythropoiesis in the yolk sac; these cells can be identified at approximately four to five weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/2\">",
"     2",
"    </a>",
"    ]. A transition is made to normoblastic erythropoiesis at approximately six weeks gestation. At this time, blood formation begins in the liver, which is the primary organ of hematopoiesis from the third to sixth month of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/2\">",
"     2",
"    </a>",
"    ]. At approximately the third month of gestation, hematopoiesis begins in the spleen, thymus, and lymph nodes. The liver and spleen continue to produce blood cells into the first week of postnatal life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone marrow hematopoiesis begins around the fourth month of gestation and increases throughout intrauterine development. After birth, further marrow volume expansion occurs. Throughout gestation, hematopoiesis is primarily under fetal control and is only partially influenced by maternal factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythropoiesis decreases dramatically after birth. RBC production decreases by a factor of 2 to 3 in the first few days of life and by a factor of 10 in the week following birth, resulting in the &ldquo;physiologic anemia of infancy&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/2\">",
"     2",
"    </a>",
"    ]. This decrease is initiated by the increase in tissue oxygen level that occurs at birth and is accompanied by a decrease in erythropoietin production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Erythropoietin levels in term infants are lowest at one month and highest at two months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/3\">",
"     3",
"    </a>",
"    ]. RBC production is at a minimum during the second week after birth and subsequently rises to maximum values at approximately three months. The net result of these changes is a hemoglobin level that typically reaches a nadir at six to nine weeks of age (sometimes referred to as \"physiologic anemia\") (",
"    <a class=\"graphic graphic_figure graphicRef81464 \" href=\"mobipreview.htm?12/54/13166\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low hemoglobin levels in preterm infants may be more pronounced because of the shorter life span of preterm RBCs. The mean half-life of RBCs for term infants is 23.3 days, as compared with 16.6 days in preterm infants, and 26 to 35 days in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=see_link&amp;anchor=H8#H8\">",
"     \"Red blood cell survival: Normal values and measurement\", section on 'Red blood cell half-time'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20792?source=see_link\">",
"     \"Anemia of prematurity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants presenting with RBC membrane abnormalities, such as hereditary spherocytosis, may develop anemia in the neonatal period because of the combination of decreased erythropoiesis that follows birth, the concomitant increase (normalization) in splenic filtration and phagocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/6\">",
"     6",
"    </a>",
"    ], and a shorter red cell life span. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=see_link&amp;anchor=H3#H3\">",
"     \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\", section on 'Signs and symptoms according to age'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATIONS OF ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemias may be classified on either a physiologic or a morphologic basis. Approaching the evaluation of an anemic patient using one or both of these classification schemes helps to narrow the diagnostic possibilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physiologic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia may be classified in two broad categories based on the reticulocyte count, which serves as a marker of whether erythropoiesis is suppressed or active (",
"    <a class=\"graphic graphic_algorithm graphicRef54266 \" href=\"mobipreview.htm?6/61/7123\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disorders resulting in an inability to adequately produce red blood cells (ie, bone marrow depression). These disorders are generally associated with a lower than expected reticulocyte response.",
"     </li>",
"     <li>",
"      Disorders resulting in rapid RBC destruction (hemolysis) or RBC losses from the body (bleeding). These disorders are generally associated with a robust reticulocyte response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18371508\">",
"    <span class=\"h3\">",
"     Reticulocyte response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reticulocytes are the youngest red cells in the circulation, and are identified by the presence of residual RNA, which gives them a blue tint on standard Wright-Giemsa stains (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 1",
"    </a>",
"    ). They are quantitated by staining with vital dyes, such as new",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/61/20438?source=see_link\">",
"     methylene blue",
"    </a>",
"    or thiazole orange, and are reported as a percentage of the red blood cell population (",
"    <a class=\"graphic graphic_picture graphicRef74294 \" href=\"mobipreview.htm?35/61/36822\">",
"     picture 2",
"    </a>",
"    ). After the first few months of life, the mean reticulocyte percentage is the same as that of the adult, approximately 1.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In patients with anemia, the reticulocyte percentage must be interpreted in relation to the reduced number of red blood cells. The simplest approach is to calculate the absolute reticulocyte count (ARC) as follows:",
"   </p>",
"   <p>",
"    Absolute reticulocyte count = percent reticulocytes x red blood cell",
"    <span class=\"nowrap\">",
"     count/L",
"    </span>",
"   </p>",
"   <p>",
"    The ARC is calculated and reported by many automated cell counters. In a patient with anemia, ARC values within the normal range (less than 100 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    generally indicate an inappropriately low erythropoietic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/7\">",
"     7",
"    </a>",
"    ]. Other reticulocyte indices (the corrected reticulocyte count and the reticulocyte production index) are sometimes used to correct for the degree of anemia, as described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Reticulocyte response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ARC is an indication of bone marrow erythropoietic activity. Thus, anemia with an elevated ARC suggests active erythropoiesis in response to hemolysis, acute blood loss, or recent institution of replacement therapy (eg, successful treatment of iron or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency), or recovery from a transient episode of erythroblast suppression. By contrast, anemia with a normal or low ARC indicates a suboptimal bone marrow response and is suggestive of marrow aplasia, infiltration with malignant cells, depression caused by infection or other toxic agents, or suboptimal production of erythropoietin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link&amp;anchor=H38#H38\">",
"     \"Approach to the adult patient with anemia\", section on 'Reticulocyte count'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    These two categories are not mutually exclusive, however. Although patients generally have one major etiology for their anemia, hemolysis or blood loss may co-exist with bone marrow suppression. As an example, a child with sickle cell disease will have life-long hemolysis, anemia, and a brisk reticulocyte response. However, during times of infection, the child&rsquo;s bone marrow may be suppressed, as evidenced by a reduction in the reticulocyte response and a consequent worsening of the anemia. In other cases, the reticulocyte count depends on the phase of the illness. As an example, the reticulocyte count is low in a child during the acute phase of transient erythroblastopenia of childhood or transient bone marrow suppression caused by a viral illness. However, during the recovery phase from these disorders, children may have elevated reticulocyte counts, as the bone marrow recovers and responds to the anemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=see_link&amp;anchor=H11#H11\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Transient erythroblastopenia of childhood (TEC)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Morphologic classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemias also may be classified according to RBC morphology, reflected by indices of RBC size (mean corpuscular volume, MCV), hemoglobin content (mean corpuscular hemoglobin, MCH), or hemoglobin concentration (mean corpuscular hemoglobin concentration, MCHC) (",
"    <a class=\"graphic graphic_table graphicRef57465 \" href=\"mobipreview.htm?5/34/5679\">",
"     table 1",
"    </a>",
"    ). The etiology of the anemia may be elucidated by using these indices, the white blood cell (WBC) and platelet counts (PLT), and the reticulocyte count (",
"    <a class=\"graphic graphic_algorithm graphicRef54266 \" href=\"mobipreview.htm?6/61/7123\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mean corpuscular volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean corpuscular volume (MCV) is the most useful RBC parameter used in the workup of anemia. It is measured directly by automated blood cell counters and represents the mean value (in femtoliters, fL) of the volume of individual RBCs in the blood sample. &nbsp;",
"   </p>",
"   <p>",
"    As with the HGB and HCT, normal values for MCV vary based upon age (",
"    <a class=\"graphic graphic_table graphicRef52224 \" href=\"mobipreview.htm?18/31/18939\">",
"     table 2",
"    </a>",
"    ). In particular, infants have an increased MCV compared to older children. MCV values also increase with decreasing gestational age so that a preterm infant with a gestational age of 25 weeks will have a MCV of 119 fL compared to a value of 106 fL in a term infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/9\">",
"     9",
"    </a>",
"    ]. Microcytosis is defined as an MCV values less than 2 SC below the mean (or &lt;80 fL in adults); macrocytosis is defined as an MCV values more than 2 SD above the mean (or &gt;100 fL in adults). MCV values within two standard deviations of the mean are considered normocytic.",
"   </p>",
"   <p>",
"    The most common cause of macrocytosis in children is the use of certain medications (eg, anti-convulsants,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/55/27512?source=see_link\">",
"     zidovudine",
"    </a>",
"    , and immunosuppressive agents) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/10\">",
"     10",
"    </a>",
"    ]. Other factors include vitamin B12 or folate deficiency, liver disease, or aplastic anemia. Because reticulocytes have a greater MCV than do mature cells (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 1",
"    </a>",
"    ), patients with significant degrees of reticulocytosis may have elevated MCV values in the face of otherwise normocytic RBCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=see_link\">",
"     \"Macrocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors that reduce the MCV include iron deficiency, lead intoxication, anemia of chronic disease, and hemoglobinopathies, but not sickle cell anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mean corpuscular hemoglobin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MCHC is a calculated index (MCHC =",
"    <span class=\"nowrap\">",
"     HGB/HCT),",
"    </span>",
"    yielding a value of grams of HGB per 100 mL of RBC. Values in the normal range (33 to 34",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    indicate that cells are normochromic, whereas values lower than normal indicate the presence of hypochromia. MCHC values vary depending upon the age of the child (",
"    <a class=\"graphic graphic_table graphicRef57465 \" href=\"mobipreview.htm?5/34/5679\">",
"     table 1",
"    </a>",
"    ) with infants having a higher value than older children. MCHC also increases with decreasing gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MCHC is low in the same conditions that generate low values for MCV and MCH. Increased values for MCHC can be caused by congenital or acquired spherocytosis or other congenital hemolytic anemias in which RBCs are abnormally desiccated. This is because the RBC&rsquo;s hemoglobin concentration is relatively increased when the RBC loses membrane surface area",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    water. The hyperchromia usually can be appreciated on the peripheral smear (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"mobipreview.htm?27/1/27670\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/12\">",
"     12",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8911691\">",
"    <span class=\"h3\">",
"     Red cell distribution width",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red cell distribution width (RDW) is a quantitative measure of the variability of RBC sizes in the sample (anisocytosis). The RDW is a function of MCV and, therefore, normal values vary slightly with age. However, normal values generally are between 12 and 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/13\">",
"     13",
"    </a>",
"    ]. The RDW is especially helpful in differentiating iron deficiency from thalassemia in the pediatric patient with microcytic anemia. Patients with a RDW greater than 20 are more likely to have iron deficiency, whereas patients with normal RDW values are more likely to have thalassemia or the anemia of chronic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HISTORY AND PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical signs and symptoms of anemia vary based on the age of the child and the etiology and chronicity of the anemia. As with most other disorders in medicine, a thorough history and physical examination are important factors in evaluating the child with anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with inherited etiologies often present in childhood. Thus, when evaluating the history of an anemic patient, one must not only review the symptoms of the patient, but also ask pointed questions regarding family history. In addition, the birth history and neonatal course may provide important etiologic clues.",
"   </p>",
"   <p>",
"    In addition to the age and sex of the child, the following components should be part of the history when evaluating an anemic child:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severity and initiation of symptoms &mdash; Common symptoms of anemia include lethargy, tachycardia, and pallor. Anemic infants may present with irritability and poor oral intake. Because of the body's compensatory abilities, patients with chronic anemia may have few or no symptoms, in contrast to patients with acute anemia with similar hemoglobin values.",
"     </li>",
"     <li>",
"      Questions relating to hemolytic episodes &mdash; Specific questions regarding changes in urine color, scleral icterus, or jaundice associated with the symptoms of anemia should be asked. Hemolytic episodes that occur only in male family members may indicate the presence of a sex-linked disorder, such as glucose-6-phosphate dehydrogenase deficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=see_link\">",
"       \"Overview of hemolytic anemias in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link\">",
"       \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=see_link\">",
"       \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior CBCs, therapy or anemic episodes &mdash; Prior complete blood counts (CBCs), anemic episodes, duration, etiology, and resolution, as well as all prior therapy for anemia, should be reviewed. Prior episodes of anemia may indicate inherited forms, whereas anemia in a patient with previously documented normal blood counts suggests an acquired etiology. Patients with hemoglobinopathies resulting in the production of small (microcytic) and pale (hypochromic) RBCs, such as Hb E or the various thalassemias, may have a history of treatment on multiple occasions for an erroneous diagnosis of iron deficiency anemia, in which the RBCs are also hypochromic and microcytic. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Blood smear'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Questions about possible blood loss &mdash; Specific questions related to bleeding from the gastrointestinal tract, including changes in stool color, the identification of blood in stools, and history of bowel symptoms, should be reviewed. Teenagers may have excessive menstrual losses without realizing it. Therefore, information regarding the menstrual history including duration of periods, flow, quantitation, and saturation of tampons or pads, should be obtained. Severe or chronic epistaxis also may result in anemia from blood and iron deficiency. Indeed, epistaxis and menorrhagia may be the result of an underlying bleeding disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/15\">",
"       15",
"      </a>",
"      ]. In patients who appear to have excessive blood loss, it is important to determine whether there is a family history of inflammatory bowel disease, polyps, colorectal cancer, hereditary hemorrhagic telangiectasia, von Willebrand disease, platelet disorders, and hemophilia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3722?source=see_link&amp;anchor=H29#H29\">",
"       \"Approach to the child with bleeding symptoms\", section on 'Von Willebrand disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A very common cause of anemia in children living in low and middle income countries is the presence of intestinal nematode infection (eg, hookworm, whipworm). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2583?source=see_link\">",
"       \"Enterobiasis and trichuriasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42437?source=see_link\">",
"       \"Hookworm infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Underlying medical conditions &mdash; A careful past medical history and review of symptoms should be obtained to elucidate chronic underlying infectious or inflammatory conditions that may result in anemia. Travel",
"      <span class=\"nowrap\">",
"       to/from",
"      </span>",
"      areas of endemic infection (eg, malaria, hepatitis, tuberculosis) should be noted. Recent illnesses should be reviewed, and possible infectious etiologies for the anemia should be explored. As an example, a mild drop in hemoglobin concentration of 1 to 1.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      is not uncommon in the presence of active infection.",
"     </li>",
"     <li>",
"      Prior drug or toxin exposure &mdash; Prior medications as well as environmental toxin exposure, including the use of well water containing nitrates, should be reviewed. Any history of oxidant-induced hemolysis should be obtained. Inquiries regarding type and duration of homeopathic or herbal medications should be undertaken because children receiving these preparations may be at risk for exposure to lead and other toxins. In addition, when evaluating a child with microcytic anemia, one should ask specific questions regarding environment, housing, paint exposure, cooking materials, and use of poorly glazed ceramic pots in order to evaluate for possible lead exposure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43225?source=see_link&amp;anchor=H17#H17\">",
"       \"Screening tests in children and adolescents\", section on 'Lead poisoning'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Questions relating to diet &mdash; Questions should be primarily aimed at determining iron content in the diet and, to a lesser degree, folate and B12 content. The type of diet, type of formula (if iron fortified), and age of infant at the time of discontinuation of formula or breast milk should be documented. In addition, the amount and type of milk the patient is drinking should be determined. The presence of pica (particularly pagophagia, the eating of ice) is a useful clue to a diagnosis of lead poisoning",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      iron deficiency (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/24/394?source=see_link\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22826?source=see_link\">",
"       \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4329?source=see_link\">",
"       \"Iron requirements and iron deficiency in adolescents\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Birth history &mdash; A birth and neonatal history including infant and mother's blood type, any history of exchange or intrauterine transfusion, and a history of anemia in the early neonatal period should be obtained. Gestational age at birth is important, because premature infants may have iron or vitamin E deficiencies resulting in anemia. The presence of jaundice or need for phototherapy may signify the presence of an inherited hemolytic anemia. A prolonged newborn hospitalization is usually associated with multiple blood tests, which lead to decreased future iron stores. Microcytosis at birth should alert the physician to consider chronic intrauterine blood loss and alpha thalassemia.",
"     </li>",
"     <li>",
"      Developmental milestones &mdash; Parents should be asked questions to determine if the child has reached age-appropriate developmental milestones. Loss of milestones or developmental delay in infants with megaloblastic anemia may signify abnormalities in the cobalamin pathway and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"       folic acid",
"      </a>",
"      malabsorption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family history, race, and ethnicity &mdash; Any family history of anemia should be pursued in depth. Family members with jaundice, gallstones, or splenomegaly should be identified. Asking if family members have undergone cholecystectomy or splenectomy may aid in the identification of additional individuals with inherited hemolytic anemias. Race and ethnic background are helpful in guiding the workup for hemoglobinopathies and enzymopathies. For example, thalassemia syndromes are more common in individuals of Mediterranean and Southeast Asian descent; Hemoglobin S and C are most commonly seen in Black and Hispanic populations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical exam also may provide important clues as to the etiology of the anemia. Areas of particular importance on the physical examination include: the skin, eyes, mouth, facies, chest, hands, and abdomen (",
"    <a class=\"graphic graphic_table graphicRef50361 \" href=\"mobipreview.htm?12/0/12301\">",
"     table 3",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Pallor should be assessed by examining sites where capillary beds are visible (eg, conjunctiva, palm, and nail beds). Pallor in these locations is predictive of severe anemia, but mild and even severe anemia may be overlooked when relying solely on this physical finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/8,17\">",
"     8,17",
"    </a>",
"    ]. As an example, in a field study of 535 preschool children, clinical pallor in the conjunctiva, palm, and nail beds was detected in only 20 percent of those with HGB &lt;11.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    and 61 percent of those with severe anemia (HGB &lt;7.0",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with hemolytic processes resulting in anemia may present with signs of scleral icterus, jaundice, and hepatosplenomegaly resulting from increased red cell destruction. However, as with the clinical detection of anemia through evaluation of pallor, clinical detection of jaundice often is poor. As an example, in an emergency department setting, the clinical detection of jaundice was found to have sensitivity and specificity of only approximately 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/19\">",
"     19",
"    </a>",
"    ]. Reticulocytosis in the absence of scleral icterus, jaundice, and hepatosplenomegaly should raise the suspicion of a recovering process such as transient erythroblastopenia of childhood instead of a hemolytic process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=see_link&amp;anchor=H11#H11\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Transient erythroblastopenia of childhood (TEC)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other findings of the physical examination may indirectly lead to the explanation for the anemia. As an example, a report described two infants with anemia and auscultatory findings of borborygmi in the left lower lung fields [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/20\">",
"     20",
"    </a>",
"    ]. These findings led to the diagnosis and treatment of hiatal hernias, and the iron deficiency resolved. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LABORATORY EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The laboratory examination should begin with a complete blood count including red blood cell indices, a reticulocyte count, and a review of the peripheral blood smear. Normal ranges for HGB and HCT vary substantially with age, so it is important to use age and sex adjusted norms (",
"    <a class=\"graphic graphic_table graphicRef57465 \" href=\"mobipreview.htm?5/34/5679\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef81464 \" href=\"mobipreview.htm?12/54/13166\">",
"     figure 1",
"    </a>",
"    ). These tests will allow for morphologic evaluation of the cells, classification of the anemia based on red blood cell size, and aid in the identification of the physiologic basis for the anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/21\">",
"     21",
"    </a>",
"    ]. Measurement of total and direct bilirubin and LDH may aid in diagnosing hemolytic conditions. After the evaluation of these parameters, precise laboratory tests may be obtained to identify and confirm the etiology of the anemia.",
"   </p>",
"   <p>",
"    In the pediatric population, many blood samples obtained for anemia screening are capillary samples such as finger or heel \"sticks.\" Although these means of sampling are acceptable, one must keep in mind that HGB and HCT values may be slightly elevated in such samples as compared to venous samples when using automated counting methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This difference may be more pronounced when using microhematocrit measurements from capillary samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/13\">",
"     13",
"    </a>",
"    ]. Although the likelihood of masking significant anemia is low, borderline low values may be \"normalized\" using the capillary collection and processing method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Blood smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of the peripheral smear is an essential part of any anemia evaluation. The following features should be noted: (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=see_link\">",
"     \"Evaluation of the peripheral blood smear\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RBC size &ndash; A normal RBC should have the same diameter as the nucleus of a small lymphocyte (",
"    <a class=\"graphic graphic_picture graphicRef59683 \" href=\"mobipreview.htm?17/50/18210\">",
"     picture 4",
"    </a>",
"    ). This comparison will help the investigator identify the patient with microcytosis (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"mobipreview.htm?21/45/22232\">",
"     picture 5",
"    </a>",
"    ) or macrocytosis (",
"    <a class=\"graphic graphic_picture graphicRef74901 \" href=\"mobipreview.htm?9/45/9942\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Central pallor &ndash; The normal mature RBC is a biconcave disc (",
"    <a class=\"graphic graphic_picture graphicRef72999 \" href=\"mobipreview.htm?31/25/32158\">",
"     picture 7",
"    </a>",
"    ). As a result, RBCs on the peripheral smear demonstrate an area of central pallor, which, in normochromic RBCs, is approximately one-third the diameter of the cell (",
"    <a class=\"graphic graphic_picture graphicRef59683 \" href=\"mobipreview.htm?17/50/18210\">",
"     picture 4",
"    </a>",
"    ). Increased central pallor indicates hypochromic cells, which most often are seen in iron deficiency (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"mobipreview.htm?21/45/22232\">",
"     picture 5",
"    </a>",
"    ) and thalassemia (",
"    <a class=\"graphic graphic_picture graphicRef56728 \" href=\"mobipreview.htm?29/23/30071\">",
"     picture 8",
"    </a>",
"    ). On the other hand, spherocytes (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"mobipreview.htm?27/1/27670\">",
"     picture 3",
"    </a>",
"    ) and reticulocytes (",
"    <a class=\"graphic graphic_picture graphicRef67042 \" href=\"mobipreview.htm?31/9/31895\">",
"     picture 1",
"    </a>",
"    ) do not display central pallor, because they are not biconcave discs.",
"   </p>",
"   <p>",
"    Fragmented cells &ndash; Although the patient's overall RBC indices may be normal, review of the blood smear may reveal the presence of small numbers of fragmented cells, indicating a microangiopathic process (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=see_link\">",
"     \"Overview of hemolytic anemias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other features &ndash; Other anemias may be characterized by typical morphologic abnormalities such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sickle cells, as seen in sickle cell disease (",
"      <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"       picture 10",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=see_link\">",
"       \"Diagnosis of sickle cell syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elliptocytes, as seen in congenital elliptocytosis (",
"      <a class=\"graphic graphic_picture graphicRef63129 \" href=\"mobipreview.htm?9/61/10199\">",
"       picture 11",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=see_link\">",
"       \"Hereditary elliptocytosis: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stomatocytes, as seen in hereditary or acquired stomatocytosis (",
"      <a class=\"graphic graphic_picture graphicRef75535 \" href=\"mobipreview.htm?8/51/9015\">",
"       picture 12",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42200?source=see_link\">",
"       \"Stomatocytosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pencil poikilocytes, which can be seen in iron deficiency anemia or thalassemia (",
"      <a class=\"graphic graphic_picture graphicRef64267 \" href=\"mobipreview.htm?21/45/22232\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Target cells, as seen in the various hemoglobinopathies including thalassemia, in liver disease, and post-splenectomy (",
"      <a class=\"graphic graphic_picture graphicRef80318 \" href=\"mobipreview.htm?4/3/4151\">",
"       picture 13",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef56728 \" href=\"mobipreview.htm?29/23/30071\">",
"       picture 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9305?source=see_link\">",
"       \"Spiculated cells (echinocytes and acanthocytes) and target cells\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bite cells, as seen in Heinz body hemolytic anemia (",
"      <a class=\"graphic graphic_picture graphicRef73790 \" href=\"mobipreview.htm?25/28/26054\">",
"       picture 14",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=see_link\">",
"       \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of numerous nucleated red blood cells indicates rapid bone marrow turnover and is seen with hemolytic processes (",
"      <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"       picture 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef76666 \" href=\"mobipreview.htm?26/29/27089\">",
"       picture 15",
"      </a>",
"      ). These findings may go undetected without inspection of the peripheral smear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increases in circulating neutrophils (neutrophilia), especially in the presence of a \"left shift\" (increased numbers of band forms) or toxic changes (",
"    <a class=\"graphic graphic_picture graphicRef70248 \" href=\"mobipreview.htm?7/17/7449\">",
"     picture 16",
"    </a>",
"    ), or the presence of atypical lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef55986 \" href=\"mobipreview.htm?1/24/1410\">",
"     picture 17",
"    </a>",
"    ) suggests the possibility of infectious or inflammatory conditions. The presence of early white blood cell forms (eg, blasts) (",
"    <a class=\"graphic graphic_picture graphicRef57831 \" href=\"mobipreview.htm?24/53/25439\">",
"     picture 18",
"    </a>",
"    ) along with anemia should raise the suspicion of leukemia or lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link\">",
"     \"Approach to the patient with neutrophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=see_link\">",
"     \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Red blood cell indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red blood cell indices MCV, MCH, and MCHC are an integral part of the evaluation of the anemic child. Interpretation of these indices is discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Morphologic classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     White blood count and platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with anemia, the presence of leukopenia (low total white blood cell count), neutropenia (low total number of neutrophils),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia (low platelet count) may signify abnormal bone marrow function or increased peripheral destruction of blood cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone marrow hypoplasia may be caused by drugs or toxins, acute leukemia, or aplastic anemia.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/31/22005?source=see_link\">",
"       Folic acid",
"      </a>",
"      or vitamin B12 deficiency are characterized by ineffective erythropoiesis, and may be associated with reduced WBC and platelet counts, or hypersegmented WBC forms.",
"     </li>",
"     <li>",
"      Increased peripheral destruction reduces WBC and platelet counts in the setting of splenic hyperfunction (\"hypersplenism\"), microangiopathic hemolytic anemia (eg, hemolytic-uremic syndrome) or Evans syndrome (a variant of autoimmune hemolytic anemia). Iron deficiency can result in either thrombocytosis (common) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/24\">",
"       24",
"      </a>",
"      ] or thrombocytopenia (uncommon) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43880/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The threshold for defining anemia is a hemoglobin (HGB) or hematocrit (HCT) that is more than two standard deviations below the mean for the age- and sex-specific reference population (",
"      <a class=\"graphic graphic_table graphicRef57465 \" href=\"mobipreview.htm?5/34/5679\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef81464 \" href=\"mobipreview.htm?12/54/13166\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major causes of anemia seen in children are iron deficiency (dietary or due to blood loss), hemolysis (drug-induced, hereditary, or due to hypersplenism), hemoglobinopathies, and bone marrow suppression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22826?source=see_link\">",
"       \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=see_link\">",
"       \"Overview of hemolytic anemias in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16984?source=see_link\">",
"       \"Introduction to hemoglobin mutations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=see_link\">",
"       \"Anemia in children due to decreased red blood cell production\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Key historical factors in the assessment of a child with anemia include the severity and onset of symptoms, evidence of jaundice or blood loss (gastrointestinal symptoms and menstrual history), drug and toxin exposure, chronic disease, and family history of anemias or hemoglobinopathy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination should include a careful assessment for pallor, scleral icterus, jaundice, hepatomegaly, and splenomegaly. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders resulting in an inability to adequately produce red blood cells (ie, bone marrow depression) are usually associated with a low reticulocyte count (&lt;3 percent). Disorders resulting in rapid destruction or loss of red blood cells (hemolysis or bleeding) are usually associated with an elevated reticulocyte count. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physiologic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anemias also may be classified also according to RBC size (mean corpuscular volume, MCV), hemoglobin content (mean corpuscular hemoglobin, MCH), or hemoglobin concentration (mean corpuscular hemoglobin concentration, MCHC). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Morphologic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Normal values for MCV are high at birth and decrease with age (",
"      <a class=\"graphic graphic_table graphicRef57465 \" href=\"mobipreview.htm?5/34/5679\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52224 \" href=\"mobipreview.htm?18/31/18939\">",
"       table 2",
"      </a>",
"      ). Factors that increase MCV include certain medications (eg, anticonvulsant drugs) vitamin B12 or folate deficiency, and reticulocytosis. Factors that reduce the MCV include iron deficiency, lead intoxication, and hemoglobinopathies. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mean corpuscular volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The laboratory examination should begin with a complete blood count, including red blood cell indices, and a reticulocyte count. The MCV and reticulocyte count often provide a preliminary categorization of the anemia, which guides additional testing (",
"      <a class=\"graphic graphic_algorithm graphicRef54266 \" href=\"mobipreview.htm?6/61/7123\">",
"       algorithm 1",
"      </a>",
"      ). However, multiple factors may contribute to the anemia, and not all patients can be neatly categorized. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physiologic classification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Mean corpuscular volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Review of the peripheral blood smear is essential. The findings may support or refute the conclusions suggested by the RBC indices, or reveal features that suggest a specific cause of anemia, and helps to evaluate the possibility of a hematologic malignancy. The clinician must critically examine all blood cells and not just the red cells. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Blood smear'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/1\">",
"      Robins EB, Blum S. Hematologic reference values for African American children and adolescents. Am J Hematol 2007; 82:611.",
"     </a>",
"    </li>",
"    <li>",
"     Brugnara C, Platt OS. The neonatal erythrocyte and its disorders. In: Hematology of Infancy and Childhood, 7th, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia 2009. p.21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/3\">",
"      Kling PJ, Schmidt RL, Roberts RA, Widness JA. Serum erythropoietin levels during infancy: associations with erythropoiesis. J Pediatr 1996; 128:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/4\">",
"      Holland BM, Jones JG, Wardrop CA. Lessons from the anemia of prematurity. Hematol Oncol Clin North Am 1987; 1:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/5\">",
"      Matoth Y, Zaizov R, Varsano I. Postnatal changes in some red cell parameters. Acta Paediatr Scand 1971; 60:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/6\">",
"      Delhommeau F, Cynober T, Schischmanoff PO, et al. Natural history of hereditary spherocytosis during the first year of life. Blood 2000; 95:393.",
"     </a>",
"    </li>",
"    <li>",
"     Means RT, Glader B. Anemia: General Considerations. In: Wintrobe's Clinical Hematology, 12 Ed, Greer JP, Foerster J, Rodgers GM, et al.  (Eds), Lippincott Williams and Wilkins, Philadelphia 2009. Vol 1, p.784.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/8\">",
"      Kalter HD, Burnham G, Kolstad PR, et al. Evaluation of clinical signs to diagnose anaemia in Uganda and Bangladesh, in areas with and without malaria. Bull World Health Organ 1997; 75 Suppl 1:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/9\">",
"      Christensen RD, Jopling J, Henry E, Wiedmeier SE. The erythrocyte indices of neonates, defined using data from over 12,000 patients in a multihospital health care system. J Perinatol 2008; 28:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/10\">",
"      Pappo AS, Fields BW, Buchanan GR. Etiology of red blood cell macrocytosis during childhood: impact of new diseases and therapies. Pediatrics 1992; 89:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/11\">",
"      d'Onofrio G, Chirillo R, Zini G, et al. Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia. Blood 1995; 85:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/12\">",
"      Walters MC, Abelson HT. Interpretation of the complete blood count. Pediatr Clin North Am 1996; 43:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/13\">",
"      Thomas WJ, Collins TM. Comparison of venipuncture blood counts with microcapillary measurements in screening for anemia in one-year-old infants. J Pediatr 1982; 101:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/14\">",
"      Novak RW. Red blood cell distribution width in pediatric microcytic anemias. Pediatrics 1987; 80:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/15\">",
"      Sandoval C, Dong S, Visintainer P, et al. Clinical and laboratory features of 178 children with recurrent epistaxis. J Pediatr Hematol Oncol 2002; 24:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/16\">",
"      Geller J, Kronn D, Jayabose S, Sandoval C. Hereditary folate malabsorption: family report and review of the literature. Medicine (Baltimore) 2002; 81:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/17\">",
"      Stoltzfus RJ, Edward-Raj A, Dreyfuss ML, et al. Clinical pallor is useful to detect severe anemia in populations where anemia is prevalent and severe. J Nutr 1999; 129:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/18\">",
"      Montresor A, Albonico M, Khalfan N, et al. Field trial of a haemoglobin colour scale: an effective tool to detect anaemia in preschool children. Trop Med Int Health 2000; 5:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/19\">",
"      Hung OL, Kwon NS, Cole AE, et al. Evaluation of the physician's ability to recognize the presence or absence of anemia, fever, and jaundice. Acad Emerg Med 2000; 7:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/20\">",
"      Sinaki B, Jayabose S, Sandoval C. Iron-deficiency anemia associated with hiatal hernia: case reports and literature review. Clin Pediatr (Phila) 2010; 49:984.",
"     </a>",
"    </li>",
"    <li>",
"     Rapaport SI. Diagnosis of anemia. In: Introduction to hematology, JB Lippincott, Philadelphia 1987. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/22\">",
"      Daae LN, Hallerud M, Halvorsen S. A comparison between haematological parameters in 'capillary' and venous blood samples from hospitalized children aged 3 months to 14 years. Scand J Clin Lab Invest 1991; 51:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/23\">",
"      Bellamy GJ, Hinchliffe RF. Venous and skin puncture blood counts compared. Clin Lab Haematol 1988; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/24\">",
"      Sandoval C. Thrombocytosis in children with iron deficiency anemia: series of 42 children. J Pediatr Hematol Oncol 2002; 24:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43880/abstract/25\">",
"      Perlman MK, Schwab JG, Nachman JB, Rubin CM. Thrombocytopenia in children with severe iron deficiency. J Pediatr Hematol Oncol 2002; 24:380.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5927 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43880=[""].join("\n");
var outline_f42_54_43880=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF ERYTHROPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATIONS OF ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physiologic classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18371508\">",
"      - Reticulocyte response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Morphologic classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mean corpuscular hemoglobin concentration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8911691\">",
"      - Red cell distribution width",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HISTORY AND PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LABORATORY EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Red blood cell indices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      White blood count and platelet count",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5927|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?6/61/7123\" title=\"algorithm 1\">",
"      Evaluation of anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5927|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/54/13166\" title=\"figure 1\">",
"      Normal values for hematocrit and hemoglobin in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5927|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/9/31895\" title=\"picture 1\">",
"      Polychromatophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/61/36822\" title=\"picture 2\">",
"      Reticulocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/1/27670\" title=\"picture 3\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/50/18210\" title=\"picture 4\">",
"      Normal blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/45/22232\" title=\"picture 5\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/45/9942\" title=\"picture 6\">",
"      Macroovalocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/25/32158\" title=\"picture 7\">",
"      Red blood cell EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/23/30071\" title=\"picture 8\">",
"      Beta thalassemia trait",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 9\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/42/1703\" title=\"picture 10\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/61/10199\" title=\"picture 11\">",
"      Elliptocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/51/9015\" title=\"picture 12\">",
"      Stomatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/3/4151\" title=\"picture 13\">",
"      Target cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/28/26054\" title=\"picture 14\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/29/27089\" title=\"picture 15\">",
"      Beta thalassemia intermedia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/17/7449\" title=\"picture 16\">",
"      Toxic granulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/24/1410\" title=\"picture 17\">",
"      Atypical lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/53/25439\" title=\"picture 18\">",
"      Lymphoblasts FAB L1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5927|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/34/5679\" title=\"table 1\">",
"      Normal hematologic values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/31/18939\" title=\"table 2\">",
"      MCV variation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/0/12301\" title=\"table 3\">",
"      Physical findings in anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=related_link\">",
"      Approach to the patient with lymphocytosis or lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=related_link\">",
"      Approach to the patient with neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2583?source=related_link\">",
"      Enterobiasis and trichuriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13689?source=related_link\">",
"      Evaluation of bone marrow aspirate smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38313?source=related_link\">",
"      Evaluation of the peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15623?source=related_link\">",
"      Hereditary elliptocytosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42437?source=related_link\">",
"      Hookworm infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21767?source=related_link\">",
"      Macrocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_54_43881="Epidemiology, pathogenesis, and classification of cholangiocarcinoma";
var content_f42_54_43881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Robert C Lowe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Christopher D Anderson, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43881/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/54/43881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the intrahepatic and extrahepatic bile ducts. Although these cancers are rare in the United States, they are highly lethal because most are locally advanced at presentation.",
"   </p>",
"   <p>",
"    The epidemiology, pathology, pathogenesis, and classification of cholangiocarcinoma will be discussed here. Clinical manifestations, diagnosis, and treatment are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34728?source=see_link\">",
"     \"Treatment options for locally advanced cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=see_link\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cancers of the gallbladder and ampulla of Vater are discussed as separate disease processes, although these structures are part of the biliary drainage system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY, TUMOR CLASSIFICATION AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary tract cancers were traditionally divided into cancers of the gallbladder, the extrahepatic ducts, and the ampulla of Vater, while intrahepatic tumors were classified as primary liver cancers. More recently, the term cholangiocarcinoma has been used to refer to bile duct cancers arising in the intrahepatic, perihilar, or distal (extrahepatic) biliary tree, exclusive of the gallbladder or ampulla of Vater (",
"    <a class=\"graphic graphic_figure graphicRef52489 \" href=\"mobipreview.htm?19/12/19651\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intrahepatic cholangiocarcinomas originate from small intrahepatic ductules (termed peripheral cholangiocarcinomas) or large intrahepatic ducts proximal to the bifurcation of the right and left hepatic ducts. The extrahepatic bile ducts are divided into perihilar (including the confluence itself) and distal segments, with the transition occurring at the point where the common bile duct lies posterior to the duodenum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bismuth-Corlette classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers arising in the perihilar region have been further classified according to their patterns of involvement of the hepatic ducts (the Bismuth-Corlette classification) (",
"    <a class=\"graphic graphic_figure graphicRef75886 \" href=\"mobipreview.htm?0/36/582\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors below the confluence of the left and right hepatic ducts (Type I)",
"     </li>",
"     <li>",
"      Tumors reaching the confluence (Type II)",
"     </li>",
"     <li>",
"      Tumors occluding the common hepatic duct and either the right or left hepatic duct (Types IIIa and IIIb, respectively)",
"     </li>",
"     <li>",
"      Tumors that are multicentric, or that involve the confluence and both the right or left hepatic duct (Type IV)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bile duct tumors that involve the common hepatic duct bifurcation are referred to as Klatskin tumors or hilar cholangiocarcinoma regardless of whether they arise from the intrahepatic or extrahepatic portion of the biliary tree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/2\">",
"     2",
"    </a>",
"    ]. Perihilar tumors account for approximately 50 percent of all cholangiocarcinomas, while about 40 percent are distal extrahepatic tumors, and 10 percent or fewer are intrahepatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TNM staging classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like the Bismuth-Corlette classification, the TNM staging system for cholangiocarcinoma from the American Joint Committee on Cancer (AJCC) is based mainly upon the extent of ductal involvement by the tumor. As of the 2010 revision, the TNM classification systems for intrahepatic, hilar, and distal cholangiocarcinomas were separated and expanded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/4\">",
"     4",
"    </a>",
"    ]. Cancers of the intrahepatic bile ducts (",
"    <a class=\"graphic graphic_table graphicRef80976 \" href=\"mobipreview.htm?42/62/44012\">",
"     table 1",
"    </a>",
"    ) are now staged independently from hepatocellular cancer in recognition of the unique variables that influence outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The rare combined hepatocellular and cholangiocarcinoma (mixed hepatocholangiocarcinomas) are included in the intrahepatic bile duct classification.",
"   </p>",
"   <p>",
"    Furthermore, in response to criticisms that the prior staging system did not accurately predict resectability or survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], there are now separate staging systems for cancers of the perihilar (",
"    <a class=\"graphic graphic_table graphicRef51131 \" href=\"mobipreview.htm?4/11/4285\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/8\">",
"     8",
"    </a>",
"    ] and distal (",
"    <a class=\"graphic graphic_table graphicRef82369 \" href=\"mobipreview.htm?43/39/44668\">",
"     table 3",
"    </a>",
"    ) bile ducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/9\">",
"     9",
"    </a>",
"    ], which differ in their definitions of T stage, and the stage groupings.",
"   </p>",
"   <p>",
"    These prominent changes in the classification of bile duct cancers have improved the prognostic stratification of the TNM staging system (",
"    <a class=\"graphic graphic_figure graphicRef72346 \" href=\"mobipreview.htm?29/8/29824\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. This has obvious implications for interpretation and comparison of outcomes from trials and retrospective series that use the older 2002 as compared to the 2010 staging criteria.",
"   </p>",
"   <p>",
"    A criticism of this staging system is that vessel invasion, as detected on the final pathology specimen, affects T-stage category, but it is not indicative of local resectability. As such, the stage groupings do not serve as a guide for local therapy. A modification to the tumor staging system for perihilar tumors has been proposed that incorporates the Bismuth-Corlette classification and a more detailed assessment of major vascular invasion, as well as liver remnant volume and underlying liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangiocarcinomas account for approximately 3 percent of all gastrointestinal malignancies, with a prevalence in autopsy studies of 0.01 to 0.46 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/12\">",
"     12",
"    </a>",
"    ]. The reported incidence in the United States is one or two cases per 100,000 population.",
"   </p>",
"   <p>",
"    Incidence data from the American Cancer Society are difficult to interpret because intrahepatic bile duct cancers are included with primary liver cancers, while extrahepatic biliary cancers are in a separate category that includes gallbladder cancer. In the United States an estimated 30,640 primary liver and intrahepatic bile duct cancers are diagnosed annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/13\">",
"     13",
"    </a>",
"    ]. Data from the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) program suggest that approximately 15 percent of these are intrahepatic cholangiocarcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 10,310 cases of extrahepatic bile duct cancer are diagnosed annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/13\">",
"     13",
"    </a>",
"    ], two-thirds of which are gallbladder cancers. The remainder, approximately 3000 cases per year, are extrahepatic cholangiocarcinomas.",
"   </p>",
"   <p>",
"    For unclear reasons, the incidence of intrahepatic cholangiocarcinoma has been rising over the past two decades in Europe, North America, Asia, Japan, and Australia (but not Denmark [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/16\">",
"     16",
"    </a>",
"    ]), while rates of extrahepatic cholangiocarcinoma are declining internationally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/14-21\">",
"     14-21",
"    </a>",
"    ]. Some of these apparent differences may be due to changes in ICD (International Classification of Disease) classification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, at least some of the increase in intrahepatic cholangiocarcinomas may be attributable to new diagnostic methods for obstructive jaundice that identify biliary malignancies which previously might have gone undiagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the rising rates of intrahepatic cholangiocarcinoma have not been associated with an increase in the proportion of early stage or smaller size lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, incidence rates do not seem to be plateauing. Other studies suggest that the increasing incidence of intrahepatic cholangiocarcinoma may be related to a concomitant increase in certain risk factors such as cirrhosis, alcoholic liver disease, and hepatitis C virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/24\">",
"     24",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Risk factors'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decreased incidence of extrahepatic cholangiocarcinomas is also unexplained. In one epidemiologic study, the decline in incidence could not be attributed to time trends in known risk factors such as inflammatory bowel disease, diabetes, smoking, or exposure to thorotrast (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Risk factors'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, the incidence of biliary tract cancers increases with age; the typical patient with cholangiocarcinoma is between 50 and 70 years of age. However, patients with primary sclerosing cholangitis (PSC) and those with choledochal cysts present nearly two decades earlier [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/12,25\">",
"     12,25",
"    </a>",
"    ]. In contrast to gallbladder cancer, where female gender predominates, the incidence of cholangiocarcinoma is slightly higher in men. This probably reflects the higher incidence of PSC in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=see_link\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two precursors to cholangiocarcinoma: biliary intraepithelial neoplasia (BilIN), and intraductal papillary neoplasm (IPMN) of the bile duct; BilIN is much more common. BilIN is graded based on the extent of cellular atypia, mirroring the spectrum of precursor lesions for pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/27\">",
"     27",
"    </a>",
"    ]. IPMN of the bile duct is a macroscopic lesion similar to its pancreatic counterpart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathology of exocrine pancreatic neoplasms\", section on 'Pancreatic intraepithelial neoplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathology of exocrine pancreatic neoplasms\", section on 'Intraductal papillary-mucinous neoplasms (IPMN)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversion from normal to malignant bile epithelium through one of these precursor lesions probably requires a stepwise accumulation of successive genetic abnormalities, similar to the sequence of events that underlies colorectal carcinogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the level of understanding of the molecular pathogenesis of cholangiocarcinoma is significantly less than that of other gastrointestinal cancers. Molecularly, the precursors of carcinoma remain poorly characterized, although they appear to harbor mutations in p53 and loss of SMAD4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of the molecular pathogenesis of cholangiocarcinomas is beyond the scope of this discussion, and is well-reviewed elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/29,32\">",
"     29,32",
"    </a>",
"    ]. What follows is a brief overview of the salient points.",
"   </p>",
"   <p>",
"    A variety of molecular defects involving both oncogenes (K-ras, c-erbB-2, BRAF, the epidermal growth factor receptor (EGFR) PIK3CA, beta-catenin (CTNNB1)) and tumor suppressor genes (eg, p53, SMAD4, CDKN2A) have been described in specimens of invasive biliary tract tumors. As an example, about one-third of tumors over-express p53 (implying the presence of mutations in this tumor suppressor gene), while abnormal expression of K-ras is found in 45 to 54 percent of intrahepatic cholangiocarcinomas, and 10 to 15 percent of extrahepatic cholangiocarcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/29\">",
"     29",
"    </a>",
"    ]. These genetic alterations seem to be associated with a more aggressive tumor phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The contribution of these genetic changes to cholangiocarcinoma genesis, and their relationship to chronic inflammation, ethnic background, and carcinogen exposure remain uncertain. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Risk factors'",
"    </a>",
"    below.) At least some data suggest that p16INK4a promoter point mutations contribute to initiation and progression of cholangiocarcinoma in the setting of PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some have proposed that intrahepatic cholangiocarcinomas share some common carcinogenic steps with hepatocellular carcinoma such as loss of heterozygosity (LOH) of chromosomes 4q and 6q,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inactivation of tumor suppressor genes on chromosome 1p [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/37\">",
"     37",
"    </a>",
"    ], the striking similarity of the precursor lesions between the pancreatic ductal system and the biliary tract raise questions about a shared molecular pathogenesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13513?source=see_link&amp;anchor=H16#H16\">",
"     \"Molecular pathogenesis of exocrine pancreatic cancer\", section on 'Genetic progression model'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Molecular abnormalities may also permit an escape from immune surveillance in vivo. In one study, human cholangiocarcinoma cells were shown to evade immune surveillance by either possessing defective signaling through the Fas receptor, an important tumor suppressor that mediates apoptosis, or by increasing the expression of a Fas ligand, inducing apoptosis of invading cytotoxic T-cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for cholangiocarcinoma have been recognized, although a specific risk factor cannot be identified for many patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/39\">",
"     39",
"    </a>",
"    ]. In the United States and Europe, the main risk factors are PSC and choledochal cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSC is an inflammatory disorder of the biliary tree that leads to fibrosis and stricturing of the intrahepatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extrahepatic bile ducts. PSC is strongly associated with ulcerative colitis (UC); approximately 40 to 50 percent of patients have symptomatic colitis, while the incidence of colitis is around 90 percent in patients with PSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=see_link\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nearly 30 percent of cholangiocarcinomas are diagnosed in patients with PSC with or without UC. The annual incidence of cholangiocarcinoma in patients with PSC has been estimated to be between 0.6 and 1.5 percent per year, with a lifetime risk of 10 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. However, the incidence is much higher (30 percent or more) in autopsy series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/48\">",
"     48",
"    </a>",
"    ]. Cholangiocarcinoma develops at a significantly younger age (between the ages of 30 and 50) in patients with PSC than in patients without this condition. It is also more difficult to diagnose because of the diffusely abnormal biliary tree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/49\">",
"     49",
"    </a>",
"    ]. Over one-third of these cases are diagnosed within two years of the initial diagnosis of PSC, and the risk appears unrelated to the duration of the inflammatory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/25,44,48\">",
"     25,44,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reason why patients with PSC develop cholangiocarcinoma is not well understood, although there have been several observations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One case-control study attempted to identify specific risk factors by comparing 20 patients with PSC and hepatobiliary carcinoma (17 of whom had cholangiocarcinoma) to 20 age- and sex-matched patients with PSC without cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/50\">",
"       50",
"      </a>",
"      ]. No clinical or biochemical risk factors for the development of cancer could be identified in the year before cancer diagnosis. However, the number of patients who smoked or were former smokers was significantly higher in the cancer group.",
"     </li>",
"     <li>",
"      Alcohol consumption has been suggested to be a risk factor for the development of cholangiocarcinoma in patients with PSC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/44\">",
"       44",
"      </a>",
"      ]. One study compared 26 patients with PSC and cholangiocarcinoma with 87 patients with PSC but without tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/44\">",
"       44",
"      </a>",
"      ]. Only alcohol consumption was significantly associated with the development of cancer (odds ratio of 2.95; 95% CI of 1.04 to 8.3). However, these authors could not test for a dose-response relationship due to inadequate data, and they could not confirm the link between smoking and cholangiocarcinoma in PSC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Certain genetic polymorphisms have been implicated as risk factors for cholangiocarcinoma in PSC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of cholangiocarcinoma is heralded by rapid clinical deterioration with jaundice, weight loss, and abdominal discomfort; tumors are often detected at an advanced stage. Screening strategies are often used to diagnose disease at an early and treatable stage. Many clinicians suggest an interval physical examination, transabdominal ultrasound, and serum levels of the tumor marker CA 19-9; these tests are often recommended annually in patients without cirrhosis and semi-annually in those with cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .) Since the absence of cirrhosis does not eliminate the risk of cholangiocarcinoma in these patients, an alternative approach may involve annual or semi-annual CA 19-9, ultrasound, and endoscopic retrograde cholangiopancreatography (ERCP) with brush",
"    <span class=\"nowrap\">",
"     cytology/biopsy",
"    </span>",
"    in those patients with cellular atypia on initial ERCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of tumor markers as screening tests for cholangiocarcinoma in patients with PSC has not been established. In one three-year prospective study of 75 patients with PSC without clinical signs of cholangiocarcinoma, serum levels of CEA, CA 19-9, CA-50 and CA-242 were not useful in diagnosing bile duct cancer because of limited specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, a more recent study of 208 patients found a sensitivity, specificity, positive and negative predictive value of 78, 98, 56 and 99 percent, respectively, using an absolute CA 19-9 level of 129",
"    <span class=\"nowrap\">",
"     U/ml",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/53\">",
"     53",
"    </a>",
"    ]. A CA 19-9 level greater than 100",
"    <span class=\"nowrap\">",
"     U/ml",
"    </span>",
"    in patients with PSC who have a malignant appearing stricture has been used in lieu of tissue diagnosis for initiation of neoadjuvant therapy for cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fibropolycystic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital abnormalities of the biliary tree (Caroli's syndrome, congenital hepatic fibrosis, choledochal cysts) carry an approximately 15 percent risk of malignant change in the adult years (average age at diagnosis 34) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/47/9977?source=see_link\">",
"     \"Biliary cysts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2902?source=see_link\">",
"     \"Caroli disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Choledochal cysts are congenital cystic dilatations of the bile ducts, while Caroli's disease is a variant of choledochal cyst disease that is characterized by multiple cystic dilations of the intrahepatic biliary ducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/58\">",
"     58",
"    </a>",
"    ]. The overall incidence of cholangiocarcinoma in patients with untreated cysts is as high as 28 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the mechanism underlying carcinogenesis in these patients is unclear, it could be related to biliary stasis, chronic inflammation from reflux of pancreatic juice, or abnormalities in bile salt transporter proteins that result in unstable bile content, or deconjugation of carcinogens that were previously conjugated in the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Parasitic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Asia (particularly Thailand), infection with liver flukes of the genera Clonorchis and Opisthorchis is associated with cholangiocarcinoma of the intrahepatic bile ducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Humans are infected by consuming undercooked fish, with the adult worms inhabiting and laying eggs in the biliary system These organisms induce a chronic inflammatory state in the proximal biliary tree, presumably leading to malignant transformation of the lining epithelium. Carcinogens that are produced by bacteria in the fish and other foods, smoking, and alcohol might also act as cofactors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/55,62\">",
"     55,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cholelithiasis and hepatolithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While cholelithiasis is a well-described strong risk factor for gallbladder cancer, the association between gallstones and cholangiocarcinoma is less well established. However, at least three epidemiologic studies note an increased risk for cholangiocarcinoma among patients with symptomatic gallstone disease, but of a lower magnitude than for gallbladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=see_link&amp;anchor=H4#H4\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\", section on 'Gallstone disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a clear and strong association between chronic intrahepatic stone disease (hepatolithiasis, also called recurrent pyogenic cholangitis) and cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/66-73\">",
"     66-73",
"    </a>",
"    ]. Stone disease affecting only the intrahepatic bile ducts is exceedingly rare in the West, but is endemic in certain parts of Southeast Asia. In Taiwan, 50 to 70 percent of patients undergoing resection for cholangiocarcinoma have associated hepatolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/68,69\">",
"     68,69",
"    </a>",
"    ], while in Japan, the incidence is much lower (6 to 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14472?source=see_link\">",
"     \"Recurrent pyogenic cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of hepatolithiasis is not known, but congenital ductal abnormalities, diet, and chronic inflammation from bacterial or parasitic infections have all been implicated. The calculi are usually composed of calcium bilirubinate (brown pigment stones) rather than cholesterol. The biliary stones are thought to cause bile stasis, predisposing to recurrent bacterial infections and chronic inflammation.",
"   </p>",
"   <p>",
"    It may be difficult to identify cholangiocarcinomas arising as a complication of hepatolithiasis. However, the diagnosis should be suspected in a patient over the age of 40 who has a long history of hepatolithiasis, weight loss, elevated serum alkaline phosphatase, a serum carcinoembryonic antigen (CEA) level above 4.2",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and hepatolithiasis in either the right or both lobes of the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Toxic exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clear association exists between exposure to the radiologic contrast agent Thorotrast (a radiologic contrast agent banned in the 1960s for its carcinogenic properties) and subsequent cholangiocarcinoma; malignancy usually develops 30 to 35 years after exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/75\">",
"     75",
"    </a>",
"    ]. An increased incidence of cholangiocarcinoma has been less strongly associated with several occupations, including the auto, rubber, chemical, and wood-finishing industries. Studies on the association between smoking and alcohol intake and risk of cholangiocarcinoma are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/76-79\">",
"     76-79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lynch syndrome and biliary papillomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two genetic disorders are associated with an increased risk of cholangiocarcinoma: Lynch syndrome, and a rare inherited disorder called multiple biliary papillomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/80\">",
"     80",
"    </a>",
"    ]. The latter condition is characterized by multiple adenomatous polyps in the bile ducts, and repeated episodes of abdominal pain, jaundice, and acute cholangitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/81\">",
"     81",
"    </a>",
"    ]. Biliary papillomatosis should be considered a premalignant condition since a high proportion of these lesions (83 percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/81\">",
"     81",
"    </a>",
"    ]) undergo malignant transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV) and hepatitis C virus (HCV) as well as liver cirrhosis regardless of etiology, have been examined as risk factors for intrahepatic cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/24,61,73,83,84\">",
"     24,61,73,83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Viral hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between hepatitis C viral infection (HCV) and cholangiocarcinoma was initially suggested in 1991 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/85\">",
"     85",
"    </a>",
"    ]. Since then, several reports have noted a higher than expected rate of HCV-associated cirrhosis in patients with cholangiocarcinoma, although the risk is much lower than for hepatocellular cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/15,24,76,83,86-90\">",
"     15,24,76,83,86-90",
"    </a>",
"    ]. A prospective case control study from Japan reported the risk of developing cholangiocarcinoma in patients with cirrhosis related to HCV was 3.5 percent at 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/83\">",
"     83",
"    </a>",
"    ]. A large cohort study in the United States found a significant association between intrahepatic cholangiocarcinoma and hepatitis C after adjustment for potential confounders including cirrhosis (adjusted RR 2.55, 95% CI 1.31-4.95) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between hepatitis B viral infection (HBV) and cholangiocarcinoma has also been suggested, although the data are less compelling than for HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/73,92,93\">",
"     73,92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Nonviral chronic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with hepatocellular carcinoma, chronic liver disease of nonviral etiology also appears to be associated with intrahepatic cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/15,24,61,73,76,83,84\">",
"     15,24,61,73,76,83,84",
"    </a>",
"    ]. In a case-control study, risk factors that were significantly more prevalent among patients with intrahepatic cholangiocarcinoma included nonspecific cirrhosis (adjusted OR 27.2) and alcoholic liver disease (adjusted OR 7.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/24\">",
"     24",
"    </a>",
"    ]. A Danish cohort study that followed 11,605 persons with cirrhosis from any cause for an average of approximately six years found a significant 10-fold higher risk for intrahepatic cholangiocarcinoma among these patients compared to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between diabetes mellitus and cancer of the biliary tract has been suggested in several case-control and cohort studies. In a meta-analysis of 15 such studies, individuals with diabetes had a significantly increased risk of cholangiocarcinoma relative to non-diabetics (summary RR 1.60, 95% CI 1.38-1.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/94\">",
"     94",
"    </a>",
"    ]. The risk was significantly elevated for both intrahepatic and extrahepatic cholangiocarcinomas. Whether diabetes itself or other associated conditions (eg, obesity, hyperlipidemia) represent the true risk factors for cholangiocarcinoma is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity was linked to extrahepatic cholangiocarcinoma in a population-based case-control study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60103124\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study that included 743 patients with intrahepatic cholangiocarcinoma found that the presence of the metabolic syndrome, (defined by the presence of three of the following: elevated waist",
"    <span class=\"nowrap\">",
"     circumference/central",
"    </span>",
"    obesity, dyslipidemia, hypertension, or impaired fasting glucose) was a risk factor for intrahepatic cholangiocarcinoma (adjusted odds ratio 56) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection was an independent risk factor for intrahepatic cholangiocarcinoma in the Medicare population in the case control study described above (adjusted OR 6.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the validity of the association is uncertain given the relatively small number of cases that were identified and the possibility that at least some of the HIV infected cases may have had coexisting, undiagnosed risk factors (such as HCV infection).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     HISTOLOGY AND IMMUNOHISTOCHEMISTRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangiocarcinomas can be classified according to their location along the biliary tree (",
"    <a class=\"graphic graphic_figure graphicRef52489 \" href=\"mobipreview.htm?19/12/19651\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75886 \" href=\"mobipreview.htm?0/36/582\">",
"     figure 2",
"    </a>",
"    ). The majority (75 percent in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/26\">",
"     26",
"    </a>",
"    ]) are found in the upper one-third of the biliary tract, and two-thirds involve the bifurcation of the common hepatic duct (Klatskin tumors). Intrahepatic nonperihilar tumors (ie, peripheral cholangiocarcinomas) are the least common, accounting for fewer than 10 percent of cases in most series. Up to 7 percent of tumors are multicentric at the time of diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cholangiocarcinomas (&gt;90 percent) are adenocarcinomas, with squamous cell carcinoma being responsible for most of the remaining cases. They are graded as well, moderately or poorly differentiated.",
"   </p>",
"   <p>",
"    Adenocarcinomas are further divided into three types: nodular, sclerosing, and papillary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Sclerosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerosing (scirrhous) tumors are characterized by an intense desmoplastic reaction. The extensive fibrosis makes preoperative diagnosis by biopsy and cytology more difficult than for other tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    .) These tumors also tend to invade the bile duct wall early, and as a result, are associated with low resectability and cure rates. Intraductal spread may mimic PSC on cholangiographic studies, complicating the radiographic diagnosis. Unfortunately, most cholangiocarcinomas are of this type. In one report, 94 percent of 194 perihilar tumors were sclerotic adenocarcinomas, as were 79 of 80 distal tumors, and all nine intrahepatic cholangiocarcinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Nodular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nodular cholangiocarcinomas present as a constricting annular lesion of the bile duct. These are highly invasive tumors, and most patients have advanced disease at the time of diagnosis; thus, the resectability and cure rates are very low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Papillary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Papillary tumors are the rarest form of cholangiocarcinoma. These usually present as bulky masses in the common bile duct lumen which cause biliary obstruction early in the course of the disease. For this reason, they have the highest resectability and cure rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics that are common to all three tumor types include slow growth, a high rate of local invasion, mucin production, and a tendency to invade perineural sheaths and spread along nerves. In contrast distant metastases are distinctly uncommon in cholangiocarcinoma.",
"   </p>",
"   <p>",
"    Most intrahepatic cholangiocarcinomas are adenocarcinomas with variable desmoplastic reaction, although there are several special or unusual histological features depending on the site of origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43881/abstract/99\">",
"     99",
"    </a>",
"    ]. At the large intrahepatic bile ducts, papillary growth and periductal infiltration is typical, while tumors arising from ductules share a similar phenotype with hepatocellular carcinoma. In addition to invasive cancer, intrahepatic cholangiocarcinomas that arise in the setting of chronic biliary disease (eg, hepatolithiasis) are characterized by precancerous lesions including biliary epithelial dysplasia and carcinoma in situ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no known proteins that are differentially expressed by normal and malignant biliary epithelium, and therefore, no pathognomonic immunohistochemical test that can be used to confirm the cell type of origin. However, positive results of several types of immunohistochemical staining (cytokeratin, carcinoembryonic antigen, mucin) may be used to support a diagnosis of malignant biliary epithelium. In particular, cytokeratin-7 (CK-7) positivity is consistent with biliary tract origin (",
"    <a class=\"graphic graphic_table graphicRef58475 \" href=\"mobipreview.htm?20/45/21212\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25322780\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term cholangiocarcinoma refers to bile duct cancers arising in the intrahepatic, perihilar, or distal (extrahepatic) biliary tree, exclusive of the gallbladder or ampulla of Vater. Cancers arising in the perihilar region are further classified according to their patterns of involvement of the hepatic ducts (the Bismuth-Corlette classification) (",
"      <a class=\"graphic graphic_figure graphicRef75886 \" href=\"mobipreview.htm?0/36/582\">",
"       figure 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The latest staging classification from the American joint Committee on Cancer (AJCC) includes separate staging systems for intrahepatic, perihilar, and distal bile duct tumors, which differ in their definitions of primary tumor stage and the stage groupings. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy, tumor classification and staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of biliary tract cancer increases with age; the typical patient with cholangiocarcinoma is between 50 and 70 years old. For unclear reasons, the incidence of intrahepatic cholangiocarcinoma has been rising over the past two decades in Europe, North America, Asia, Japan, and Australia, while rates of extrahepatic cholangiocarcinoma are declining internationally. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of risk factors for cholangiocarcinoma have been recognized, although a specific risk factor cannot be identified for many patients. In the United States and Europe, the main risk factors are primary sclerosing cholangitis and choledochal cysts. There is a clear and strong association between chronic intrahepatic stone disease (hepatolithiasis, also called recurrent pyogenic cholangitis) and cholangiocarcinoma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of cholangiocarcinomas (&gt;90 percent) are adenocarcinomas, with squamous cell carcinoma being responsible for most of the remaining cases. Adenocarcinomas are further divided into three types: nodular, sclerosing, and papillary. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/1\">",
"      de Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med 1999; 341:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/2\">",
"      Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/3\">",
"      DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245:755.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.201.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/5\">",
"      Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer 2011; 117:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/6\">",
"      Zervos EE, Osborne D, Goldin SB, et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 2005; 190:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/7\">",
"      Hong SM, Pawlik TM, Cho H, et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery 2009; 146:250.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.219.",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.227.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/10\">",
"      Okabayashi T, Yamamoto J, Kosuge T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001; 92:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/11\">",
"      Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011; 53:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/12\">",
"      Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/13\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/14\">",
"      Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/15\">",
"      Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/16\">",
"      Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 2007; 99:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/17\">",
"      West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/18\">",
"      Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Williston Park) 2004; 18:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/19\">",
"      Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/20\">",
"      Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/21\">",
"      Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/22\">",
"      Khan SA, Emadossadaty S, Ladep NG, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012; 56:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/23\">",
"      Jarnagin WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 2000; 19:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/24\">",
"      Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/25\">",
"      Broom&eacute; U, Olsson R, L&ouml;&ouml;f L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/26\">",
"      Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992; 70:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/27\">",
"      Zen Y, Adsay NV, Bardadin K, et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007; 20:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/28\">",
"      Kl&ouml;ppel G, Kosmahl M. Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm? J Hepatol 2006; 44:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/29\">",
"      Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010; 28:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/30\">",
"      Nakanishi Y, Zen Y, Kondo S, et al. Expression of cell cycle-related molecules in biliary premalignant lesions: biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol 2008; 39:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/31\">",
"      Hoang MP, Murakata LA, Katabi N, et al. Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol 2002; 15:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/32\">",
"      Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004; 24:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/33\">",
"      Isa T, Tomita S, Nakachi A, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002; 49:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/34\">",
"      Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004; 24:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/35\">",
"      Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002; 123:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/36\">",
"      Tannapfel A, Benicke M, Katalinic A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/37\">",
"      Momoi H, Okabe H, Kamikawa T, et al. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin Cancer Res 2001; 7:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/38\">",
"      Que FG, Phan VA, Phan VH, et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology 1999; 30:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/39\">",
"      Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999; 10 Suppl 4:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/40\">",
"      Tung BY, Brentnall T, Kowdley KV, et al. Diagnosis and prevalence of ulcerative colitis in patients with primary sclerosing cholangitis (abstract). Hepatology 1996; 24:169A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/41\">",
"      Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/42\">",
"      Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/43\">",
"      Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994; 69:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/44\">",
"      Bergquist A, Glaumann H, Persson B, Broom&eacute; U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/45\">",
"      de Groen PC. Cholangiocarcinoma in primary sclerosing cholangitis: who is at risk and how do we screen? Hepatology 2000; 31:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/46\">",
"      Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/47\">",
"      Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/48\">",
"      Rosen CB, Nagorney DM, Wiesner RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/49\">",
"      LaRusso NF, Wiesner RH, Ludwig J, MacCarty RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/50\">",
"      Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/51\">",
"      Melum E, Karlsen TH, Schrumpf E, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008; 47:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/52\">",
"      Hultcrantz R, Olsson R, Danielsson A, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/53\">",
"      Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005; 50:1734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/54\">",
"      Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/55\">",
"      Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/56\">",
"      Scott J, Shousha S, Thomas HC, Sherlock S. Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature. Am J Gastroenterol 1980; 73:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/57\">",
"      Lipsett PA, Pitt HA, Colombani PM, et al. Choledochal cyst disease. A changing pattern of presentation. Ann Surg 1994; 220:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/58\">",
"      Dayton MT, Longmire WP Jr, Tompkins RK. Caroli's Disease: a premalignant condition? Am J Surg 1983; 145:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/59\">",
"      Watanapa P. Cholangiocarcinoma in patients with opisthorchiasis. Br J Surg 1996; 83:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/60\">",
"      Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002; 89:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/61\">",
"      Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996; 25:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/62\">",
"      Honjo S, Srivatanakul P, Sriplung H, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer 2005; 117:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/63\">",
"      Hsing AW, Gao YT, Han TQ, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2007; 97:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/64\">",
"      Ahrens W, Timmer A, Vyberg M, et al. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroenterol Hepatol 2007; 19:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/65\">",
"      Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007; 120:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/66\">",
"      Chijiiwa K, Yamashita H, Yoshida J, et al. Current management and long-term prognosis of hepatolithiasis. Arch Surg 1995; 130:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/67\">",
"      Lee CC, Wu CY, Chen GH. What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol 2002; 17:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/68\">",
"      Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol 1999; 14:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/69\">",
"      Su CH, Shyr YM, Lui WY, P'Eng FK. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 1997; 84:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/70\">",
"      Kinami Y, Noto H, Miyazaki I, et al. A study of hepatolithiasis associated with cholangiocarcinoma. Acta Hepatol Jpn 1978; 19:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/71\">",
"      Yamamoto K, Tsuchiya R, Ito I, et al. A study of cholangiocarcinoma coexisting with hepatolithiasis. Jpn J Gastroenterol Surg 1984; 17:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/72\">",
"      Okuda K, Kubo Y, Okazaki N, et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer 1977; 39:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/73\">",
"      Donato F, Gelatti U, Tagger A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/74\">",
"      Kim YT, Byun JS, Kim J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology 2003; 50:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/75\">",
"      Sahani D, Prasad SR, Tannabe KK, et al. Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging 2003; 28:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/76\">",
"      Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/77\">",
"      Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008; 14:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/78\">",
"      Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/79\">",
"      Grainge MJ, West J, Solaymani-Dodaran M, et al. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer 2009; 100:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/80\">",
"      Mecklin JP, J&auml;rvinen HJ, Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer 1992; 69:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/81\">",
"      Lee SS, Kim MH, Lee SK, et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer 2004; 100:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/82\">",
"      Taguchi J, Yasunaga M, Kojiro M, et al. Intrahepatic and extrahepatic biliary papillomatosis. Arch Pathol Lab Med 1993; 117:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/83\">",
"      Kobayashi M, Ikeda K, Saitoh S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000; 88:2471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/84\">",
"      Sorensen HT, Friis S, Olsen JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/85\">",
"      Nagaoka T, Ohkawa S, Ito Y, et al. [A case of minute cholangiocellular carcinoma which was found in the follow-up periods of liver cirrhosis and was indistinguishable from hepatocellular carcinoma on hepatic angiography]. Nihon Shokakibyo Gakkai Zasshi 1991; 88:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/86\">",
"      Hsing AW, Zhang M, Rashid A, et al. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer 2008; 122:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/87\">",
"      Yamamoto S, Kubo S, Hai S, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 95:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/88\">",
"      Liu XF, Zou SQ, Qiu FZ. Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary Pancreat Dis Int 2003; 2:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/89\">",
"      Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002; 17:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/90\">",
"      Lu H, Ye MQ, Thung SN, et al. Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients. Chin Med J (Engl) 2000; 113:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/91\">",
"      El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009; 49:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/92\">",
"      Lee CH, Chang CJ, Lin YJ, et al. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 2009; 100:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/93\">",
"      Peng NF, Li LQ, Qin X, et al. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann Surg Oncol 2011; 18:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/94\">",
"      Jing W, Jin G, Zhou X, et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012; 21:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/95\">",
"      Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/96\">",
"      Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/97\">",
"      Jarnagin WR, Bowne W, Klimstra DS, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005; 241:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/98\">",
"      Martin RC, Klimstra DS, Schwartz L, et al. Hepatic intraductal oncocytic papillary carcinoma. Cancer 2002; 95:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43881/abstract/99\">",
"      Nakanuma Y, Harada K, Ishikawa A, et al. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10:265.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 663 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43881=[""].join("\n");
var outline_f42_54_43881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25322780\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY, TUMOR CLASSIFICATION AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bismuth-Corlette classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TNM staging classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fibropolycystic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Parasitic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cholelithiasis and hepatolithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Toxic exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lynch syndrome and biliary papillomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Viral hepatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Nonviral chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60103124\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HISTOLOGY AND IMMUNOHISTOCHEMISTRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Sclerosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Nodular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Papillary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25322780\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/663|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/12/19651\" title=\"figure 1\">",
"      Anatomic classification biliary cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/36/582\" title=\"figure 2\">",
"      Bismuth-Corlette classification of biliary tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/8/29824\" title=\"figure 3\">",
"      SEER surv intrahep cholang",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/62/44012\" title=\"table 1\">",
"      TNM intrahep cholangio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/11/4285\" title=\"table 2\">",
"      TNM perihilar cholangio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/39/44668\" title=\"table 3\">",
"      TNM distal cholangio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/45/21212\" title=\"table 4\">",
"      Cytokeratin stain pattern CUP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/47/9977?source=related_link\">",
"      Biliary cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/53/2902?source=related_link\">",
"      Caroli disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=related_link\">",
"      Epidemiology and pathogenesis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/46/15082?source=related_link\">",
"      Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13513?source=related_link\">",
"      Molecular pathogenesis of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14472?source=related_link\">",
"      Recurrent pyogenic cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=related_link\">",
"      Systemic therapy for advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34728?source=related_link\">",
"      Treatment options for locally advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_54_43882="Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects";
var content_f42_54_43882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Toni K Choueiri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Guru Sonpavde, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/54/43882/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/54/43882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1651224889\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of angiogenesis inhibitors in cancer therapy is expanding. Following the recognition of the role of angiogenesis in promoting tumor growth",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/1\">",
"     1",
"    </a>",
"    ], multiple trials have shown that angiogenesis inhibitors yield incremental improvements in outcomes for a variety of advanced solid tumors.",
"   </p>",
"   <p>",
"    Several classes of agents are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      is a monoclonal antibody against vascular endothelial growth factor (VEGF) that inhibits binding of the normal VEGF ligand to its receptor. In the United States, the approval of bevacizumab for metastatic colorectal cancer (mCRC) by the Food and Drug Administration (FDA) ushered in the modern era of antiangiogenic therapy. The European Medicines Agency (EMA) granted approval for bevacizumab in mCRC in January 2006. Subsequently, bevacizumab has been approved by both the FDA and EMA for treatment of metastatic non-squamous non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and glioblastoma multiforme. The EMA has also approved bevacizumab for treatment of ovarian cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/2\">",
"       2",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H23212813#H23212813\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779238#H525779238\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Role of bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=see_link&amp;anchor=H24#H24\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11832?source=see_link&amp;anchor=H11858079#H11858079\">",
"       \"The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum\", section on 'Bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       Aflibercept",
"      </a>",
"      , another VEGF ligand inhibitor, is a VEGF receptor (VEGFR) fusion molecule that binds to and inhibits VEGF binding to all classes of VEGFR as well as placenta growth factor (PlGF) binding to VEGFR1; it is approved in combination with chemotherapy for recurrent mCRC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H23212877#H23212877\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Aflibercept'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multiple orally active tyrosine kinase inhibitors (TKIs) that block angiogenesis by inhibiting the actions of VEGF and other growth factors (eg, platelet-derived growth factor) are available, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"       vandetanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"       cabozantinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       regorafenib",
"      </a>",
"      . These drugs have received approval for treatment of a variety of tumors, including RCC, hepatocellular cancer (HCC), gastrointestinal stromal tumors (GIST), medullary thyroid cancer (MTC), pancreatic neuroendocrine tumors (PNET), soft tissue sarcomas (STS), refractory chronic myelogenous leukemia, and refractory mCRC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=see_link&amp;anchor=H3#H3\">",
"       \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\", section on 'VEGF TK inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=see_link&amp;anchor=H18#H18\">",
"       \"Systemic treatment for advanced hepatocellular carcinoma\", section on 'Sorafenib'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=see_link&amp;anchor=H25772305#H25772305\">",
"       \"Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors\", section on 'Alternative treatment strategies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23288?source=see_link&amp;anchor=H2#H2\">",
"       \"Chemotherapy and immunotherapy for medullary thyroid cancer\", section on 'Tyrosine kinase inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=see_link&amp;anchor=H190949089#H190949089\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Small molecule TK inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/11/41146?source=see_link&amp;anchor=H26#H26\">",
"       \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Antiangiogenic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=see_link&amp;anchor=H12149527#H12149527\">",
"       \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Ponatinib'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56909045#H56909045\">",
"       \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Regorafenib'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the expanding use of agents that target the VEGF signaling pathway in cancer therapy, it is increasingly recognized that they are associated with a wide spectrum of toxicities which, in a small number of cases, may be fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. While some adverse effects are shared with conventional chemotherapeutic agents (which were designed to target cell division), many are unique and not typically observed with conventional cytotoxics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class-effects of VEGF axis inhibition by both VEGF-ligand and VEGFR TKIs include cardiovascular effects (hypertension, thromboembolism, left ventricular dysfunction) and non-cardiovascular effects (proteinuria, bleeding, delayed wound healing, gastrointestinal perforation, fatigue, and dysphonia).",
"      <br/>",
"      <br/>",
"      Other rare class-effects of VEGF axis inhibition include reversible posterior leukoencephalopathy (RPLS), osteonecrosis of the jaw (ONJ), and microangiopathic hemolysis.",
"     </li>",
"     <li>",
"      The antiangiogenic TKIs have additional class effects, including gastrointestinal events (diarrhea, nausea), thyroid dysfunction, fatigue, stomatitis, myelosuppression, and cutaneous effects (including hand-foot syndrome). In addition, severe and occasionally fatal hepatic toxicities have been described with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      . Rare effects include pancreatic enzyme elevations, hypoglycemia, and QTc prolongation.",
"      <br/>",
"      <br/>",
"      Some of these side effects may reflect the promiscuity of kinase inhibitors, which inhibit multiple other receptors in addition to VEGFRs (referred to as off-target activity).",
"     </li>",
"     <li>",
"      Some toxicities are mostly reported with certain agents, such as nasal septal perforation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , and sarcopenia with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these adverse effects are serious, and some may be fatal. (See",
"    <a class=\"local\" href=\"#H89432012\">",
"     'Risk of fatality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic review will cover the non-cardiovascular adverse effects of the antiangiogenic agents. Cardiovascular toxicities from angiogenesis inhibitors and thrombotic complications of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/33/33303?source=see_link\">",
"     pomalidomide",
"    </a>",
"    , drugs that have immunomodulatory as well as some antiangiogenic activity, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H89432012\">",
"    <span class=\"h1\">",
"     RISK OF FATALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have demonstrated a small risk of fatal adverse events (approximately 1.5 to 2.5 percent, relative risk [RR] 1.5-2.2) with both antiangiogenic TKIs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In one analysis, bevacizumab was associated with an increased risk of fatal events in combination with taxanes or platinum agents (RR 3.49) but not in combination with other agents (RR 0.85) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two meta-analyses, hemorrhage was the most common fatal adverse event with both classes of agents; other causes of treatment-related death were cardiac, gastrointestinal tract perforation, hepatic dysfunction, infection, and cerebrovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In another meta-analysis examining fatal events with antiangiogenic TKIs, heart failure, pulmonary emboli, hepatic failure, intestinal perforation, and",
"    <span class=\"nowrap\">",
"     pneumonia/respiratory",
"    </span>",
"    failure were numerically higher on the antiangiogenic TKIs treatment arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study, the increased RR for death with the antiangiogenic TKIs was statistically significant for RCC but not for lung cancer. However, the increased risk seen in patients treated for RCC may be ascribed partly to increased exposure time to the antiangiogenic TKIs in these patients relative to those with lung cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651224896\">",
"    <span class=\"h1\">",
"     CLASS EFFECTS OF VEGF INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651225341\">",
"    <span class=\"h2\">",
"     Proteinuria/nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both VEGF ligand inhibiting agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    ) and the small molecule antiangiogenic TKIs are associated with proteinuria, which is rarely in the nephrotic range (&gt;3.5",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours), and even more rarely, associated with the nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Hypertension frequently accompanies proteinuria (see below). Proteinuria is usually an asymptomatic event detected only through laboratory analysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link&amp;anchor=H1#H1\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Introduction and terminology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21639449#H21639449\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall incidence of mild proteinuria in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ranges from 21 to up to 63 percent, but grade 3 or 4 proteinuria (defined as 3+ on dipstick, &gt;3.5 g of",
"    <span class=\"nowrap\">",
"     protein/24",
"    </span>",
"    hours, or the nephrotic syndrome) affects approximately 2 percent of treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fewer data are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    , but in a phase III trial, proteinuria developed in 62 percent of patients treated with aflibercept plus chemotherapy (versus 41 percent of those treated with chemotherapy alone), and it was severe (grade 3 or 4) in 7.8 versus 1.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with renal cell cancer treated with antiangiogenic TKIs, the incidence of mild and asymptomatic proteinuria also ranges from 21 to 63 percent, but heavy proteinuria is reported in up to 6.5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of proteinuria with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    may be lower (7 percent all grade in one trial, 1 percent grade 3 or 4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although proteinuria appears to be an effect common to all agents targeting the VEGF pathway, the factors associated with the occurrence and severity of proteinuria in patients treated with the individual agents are incompletely characterized. Preexisting renal disease (including higher baseline urine protein levels and hypertension) and a diagnosis of renal cell carcinoma, as compared to other malignant diseases, may be predisposing factors for all agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/11,15-17\">",
"     11,15-17",
"    </a>",
"    ]. Others suggest a dose dependency of proteinuria in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and an increase in risk when bevacizumab is combined with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. The relationship between treatment duration and proteinuria and whether the development of proteinuria serves as a surrogate marker of antitumor efficacy is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact mechanism underlying proteinuria is not known. Reports of renal biopsies among patients with proteinuria receiving VEGF-targeted agents are sparse; when reported, the most common causative agent was",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . Histologic findings have included thrombotic microangiography, collapsing glomerulopathy, and isolated reports of cryoglobulinemic and immune complex glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/10,18-22\">",
"     10,18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in rodents have demonstrated that VEGF plays a major role in endothelial development and the maintenance of a fenestrated endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/23\">",
"     23",
"    </a>",
"    ] and in repair of glomerular endothelial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/24\">",
"     24",
"    </a>",
"    ]. Renal thrombotic microangiopathy has been recapitulated in a mouse model in which VEGF was locally ablated within the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/18\">",
"     18",
"    </a>",
"    ]. It is hypothesized, although not proven, that renal thrombotic microangiopathy leads to glomerular capillary endothelial injury, which in turn, is responsible for proteinuria. Hypertension, which commonly accompanies proteinuria, could also contribute to endothelial injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651225348\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implications of asymptomatic proteinuria from VEGF inhibitors are unknown and it is possible that the vast majority of cases have no clinical consequences. However, proteinuria has been linked to adverse cardiovascular outcomes and progression to end stage renal disease in patients with chronic kidney disease, and as such, proteinuria is identified as a target for treatment in kidney diseases in general. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link&amp;anchor=H5#H5\">",
"     \"Secondary factors and progression of chronic kidney disease\", section on 'Proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence-based guidelines for management of proteinuria in patients receiving VEGF-targeted agents are lacking. The FDA-approved manufacturer's labeling for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    recommends intermittent monitoring for the development of proteinuria but does not provide specific recommendations, except temporary withholding of the drug if protein excretion if &gt;2",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours, and permanent discontinuation for patients who develop the nephrotic syndrome. However, this complication is uncommon and many institutions do not routinely dipstick urine prior to each dose of bevacizumab. In a report of 243 patients receiving bevacizumab for a metastatic solid tumor, the development of proteinuria affected treatment decisions in only 2 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Baseline and periodic urinalysis is also recommended during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    , with treatment interruption or discontinuation for patients who develop moderate to severe proteinuria (defined as &ge;3",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours for pazopanib but undefined for axitinib) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/26\">",
"     26",
"    </a>",
"    ]. There are no guidelines for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    ; however, good clinical practice dictates baseline and periodic assessment for proteinuria (every eight weeks; more frequently if significant proteinuria is detected) for these agents also.",
"   </p>",
"   <p>",
"    Although discontinuation of the anti-VEGF agent results in significant reduction in proteinuria, persistence is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/27\">",
"     27",
"    </a>",
"    ]. For patients with persisting proteinuria, in the absence of specific therapy directed against the underlying disease, lowering of intraglomerular pressure, which may reduce protein excretion, may be achieved by the administration of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker. There are no controlled studies, however, evaluating the benefit of these agents in patients with proteinuria related to therapy with a VEGF inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=see_link&amp;anchor=H13#H13\">",
"     \"Microalbuminuria in type 2 diabetes mellitus\", section on 'ACE inhibitors/ARBs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=see_link&amp;anchor=H18#H18\">",
"     \"Microalbuminuria in type 1 diabetes mellitus\", section on 'Angiotensin inhibition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Proteinuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651225355\">",
"    <span class=\"h2\">",
"     Other renal problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less commonly, nephritic syndrome, acute renal dysfunction, and proliferative glomerulonephritis have been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/28\">",
"     28",
"    </a>",
"    ]. Renal insufficiency and diabetes insipidus have been reported in clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    in medullary thyroid cancer and lung cancer, although causality has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651225362\">",
"    <span class=\"h2\">",
"     Alterations in red blood cell production",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mouse models, very high-grade VEGF inhibition is associated with reversible erythrocytosis, reticulocytosis, and increases in red blood cell mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/31\">",
"     31",
"    </a>",
"    ]. Cyclic changes in hemoglobin levels have been noted in patients with metastatic renal cell cancer receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In addition, sunitinib administration is frequently associated with macrocytosis with an elevated mean corpuscular volume (MCV) in the absence of folate deficiency.",
"   </p>",
"   <p>",
"    Although the mechanism underlying erythrocytosis is not established, it could be due either to temporary loss of intravascular fluid volume (ie, relative polycythemia) caused by inhibition of VEGFR-2 and subsequent reduction in nitric oxide, or secondarily by an increase in erythropoiesis driven by hepatic erythropoietin synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/32,34\">",
"     32,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary erythrocytosis has also been described in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Intriguingly, in a study of 10 patients with RCC who developed secondary erythrocytosis with bevacizumab, the peak increase of hemoglobin correlated with longer progression-free survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227378\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;All VEGF-targeted agents have been associated with an increased risk of hemorrhage. Perturbation of endothelial cell function by targeting molecules expressed on the endothelial cell surface, such as VEGFRs, may heighten susceptibility to bleeding. In addition, direct antitumor activity leading to cavitation in an area of tumor that contains poorly developed neovessels that lack a well-formed musculature has been postulated to cause pulmonary hemorrhage, particularly in squamous cell lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/19\">",
"     19",
"    </a>",
"    ]. Finally, coexisting thrombocytopenia may aggravate bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227385\">",
"    <span class=\"h3\">",
"     Bevacizumab and aflibercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have demonstrated an increase in the risk of bleeding with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ; most commonly this is grade 1 epistaxis, but serious, and in some cases, fatal hemorrhagic events, including hemoptysis, gastrointestinal bleeding, hematemesis, intracerebral hemorrhage, epistaxis, and vaginal bleeding, have occurred.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial-level meta-analysis, the risk of major bleeding in patients with advanced solid tumors who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (at any dose) was 2.8 percent (95% CI 2.1-3.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/37\">",
"       37",
"      </a>",
"      ]. The overall RR of high-grade bleeding was 1.60 and was lower with at 2.5",
"      <span class=\"nowrap\">",
"       mg/kg/week",
"      </span>",
"      (RR 1.27) compared to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week (RR 3.02). Higher risks were observed in patients with NSCLC (RR 3.41), RCC (RR 6.37), and colorectal cancer (RR 9.11) receiving bevacizumab 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week.",
"     </li>",
"     <li>",
"      In another trial-level meta-analysis, the incidence of all-grade hemorrhage with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      was 30 percent, and 3.5 percent were high grade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/38\">",
"       38",
"      </a>",
"      ]. The overall RR for any grade bleeding was 2.48, with RRs of 3.02 and 2.01 for 5 and 2.5",
"      <span class=\"nowrap\">",
"       mg/kg/week,",
"      </span>",
"      respectively. Most hemorrhages occurred within the first five months of treatment. The most common type of hemorrhage was epistaxis, although hemoptysis, gastrointestinal bleeding, intracerebral hemorrhage, and intratumoral hemorrhage also occurred. The RR of high-grade bleeding was 1.91 and the risk of fatal bleeding was low (0.8 percent) and significantly elevated only in lung cancer (RR 5.02).",
"     </li>",
"     <li>",
"      In contrast to these two studies, in an individual patient level meta-analysis evaluating the risk of arterial thromboembolism, the risk of serious bleeding was modestly increased with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      but the difference was not statistically significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/39\">",
"       39",
"      </a>",
"      ]. Grade 3 and 4 bleeding events occurred in 3.7 percent of bevacizumab-treated patients versus 1.8 percent of control patients. The rate of bleeding events per 100 person-years was 5.3 with bevacizumab and 3.3 for controls (ratio=1.6, 95% CI 0.86 to 2.97; p=0.13). Baseline or on-study",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use was associated with a modest 1.3-fold increase in the risk of grade 3 or 4 bleeding events in both treatment groups (from 3.6 to 4.7 percent in bevacizumab-treated patients and from 1.7 to 2.2 percent for control subjects).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the risk of severe (grade 3 or 4) bleeding with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was not increased in patients receiving primary anticoagulant prophylaxis for venous thromboembolic disease, including low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in an analysis of the BRiTE observational registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less information is available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    . In a phase III trial, epistaxis was noted in 28 percent of aflibercept-treated patients (versus 7 percent with chemotherapy alone), and the rate of grade 3 or 4 hemorrhage was 3 versus 1.7 percent in the control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227392\">",
"    <span class=\"h3\">",
"     Antiangiogenic TKIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of bleeding has also been reported for the antiangiogenic TKIs. In a trial-level meta-analysis of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    for a variety of malignant diseases, the overall incidence of all grade and high-grade bleeding events was 16.7 and 2.4 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/41\">",
"     41",
"    </a>",
"    ]. The RR for all-grade bleeding events associated with sunitinib or sorafenib was significantly higher when compared to controls (RR 2.0, p=0.015). However, the risk for high-grade bleeding was not significantly elevated compared to controls (RR 1.16, p=0.555). There were no significant differences in these results when the analysis was stratified according to underlying malignancy (RCC versus others) or agent used.",
"   </p>",
"   <p>",
"    As noted above, in two separate meta-analyses that examined fatal adverse events with antiangiogenic TKIs and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in advanced solid tumors, hemorrhage was observed to be the most common toxic cause of death with both classes of VEGF inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H89432012\">",
"     'Risk of fatality'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227399\">",
"    <span class=\"h3\">",
"     Special categories of bleeding",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227407\">",
"    <span class=\"h4\">",
"     Intracranial bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised about a potential increase in the risk of intracerebral hemorrhage (ICH) in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    who have brain metastases. In a phase I study, bevacizumab was associated with fatal ICH in a patient with an unsuspected intracerebral metastasis from hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/42\">",
"     42",
"    </a>",
"    ]. Based on this single anecdotal report, patients with brain metastases have been excluded from most clinical trials evaluating bevacizumab. However, subsequent accumulation of data has demonstrated that the risk of ICH in patients with treated, nonhemorrhagic brain metastases or with previously undiagnosed brain metastases or with treatment-emergent brain metastases does not appear to be significantly greater than that of patients with brain metastases who are not treated with bevacizumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/43-51\">",
"     43-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A safety analysis analyzed the incidence of ICH with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in approximately 13,000 patients from randomized and nonrandomized trials conducted in patients with breast, non-small cell lung, pancreatic, renal cell, or colorectal cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/43\">",
"       43",
"      </a>",
"      ]. Patients with central nervous system (CNS) metastases were at similar risk of developing ICH, independent of bevacizumab therapy. Among 187 patients who were found to have occult brain metastases, 3 of 91 bevacizumab treated patients developed grade 4 ICH, compared with one fatal ICH among 96 controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, 115 patients with previously treated brain metastases were given",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in combination with systemic chemotherapy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      as first or second-line therapy for non-small cell lung cancer (NSCLC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/44\">",
"       44",
"      </a>",
"      ]. At a median on-study duration of six months, there were no reported episodes of ICH (95% CI 0.0-3.3 percent). Eighty percent had received prior whole brain radiation with or without radiosurgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neurosurgery, and 19.1 percent had received radiosurgery alone, and one patient (0.9 percent) underwent neurosurgery alone. A small proportion of patients were on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (8.7 percent) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (7.0 percent), and 9.6 percent of patients were on daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      . Of the five patients who developed a pulmonary or non-CNS, nonpulmonary hemorrhage while receiving bevacizumab, none had a risk factor for hemorrhage.",
"     </li>",
"     <li>",
"      An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in patients with NSCLC and brain metastases concluded that neither",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      nor",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"        sunitinib",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"        sorafenib",
"       </a>",
"      </span>",
"      increased the risk of ICH in patients with treatment-emergent, pretreated, or untreated occult brain metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779231#H525779231\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Even in glioblastomas, which are highly vascular, ICH appears to be uncommon; this adverse event occurred in 0 to 3.8 percent of patients across studies of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. However, concurrent anticoagulation and bevacizumab therapy may increase the risk of hemorrhage in these patients (11 versus 3 percent overall rate of ICH in anticoagulated versus non-anticoagulated patients in one retrospective review [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/49\">",
"       49",
"      </a>",
"      ]). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H530204220#H530204220\">",
"       \"Management of recurrent malignant gliomas\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CNS metastases from renal cell cancer have a propensity to bleed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Stroke'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      An early report suggested a high incidence of ICH in patients with metastatic RCC and brain metastases who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/52\">",
"       52",
"      </a>",
"      ]. In a retrospective review of 67 patients, five died of an intracerebral hemorrhage within two weeks after initiating therapy with sunitinib or sorafenib, four of whom had known brain metastases, all treated with RT. However, this could not be confirmed in an expanded access series analyzed the safety and efficacy of sunitinib treatment in 4564 patients with advanced RCC, of whom 321 had brain metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/50\">",
"       50",
"      </a>",
"      ]. Only one patient with a brain metastasis had a mild, treatment-related cerebral hemorrhage.",
"      <br/>",
"      <br/>",
"      Data regarding ICH risk with other antiangiogenic TKIs used to treat RCC are lacking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these results suggest that patients with a history of treated nonhemorrhagic brain metastases probably should not be excluded from systemic therapy with a VEGF inhibitor as long as they are not on concurrent anticoagulation. In practice, antiangiogenic therapy is generally held during local therapy for brain metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in an anticoagulated patient with a recurrent primary brain tumor is more complex and must be based upon a careful assessment of the risk to benefit ratio. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H530204220#H530204220\">",
"     \"Management of recurrent malignant gliomas\", section on 'Side effects'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227415\">",
"    <span class=\"h4\">",
"     Pulmonary hemorrhage and cavitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hemorrhage is a known complication of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , especially in patients with squamous cell NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/19,53,54\">",
"     19,53,54",
"    </a>",
"    ]. In a phase II trial, 4 of 13 squamous carcinomas compared with 2 of 54 adenocarcinomas manifested severe hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/19\">",
"     19",
"    </a>",
"    ]. As a result of this finding, subsequent phase III trials in NSCLC excluded squamous histology, and rates of pulmonary hemorrhage have been low. As examples (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ECOG 4599 trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , grade &ge;3 pulmonary hemorrhage was reported in eight (1.9 percent) bevacizumab recipients (five of which were fatal), while only one grade 3 event (0.2 percent) occurred in the control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the AVAiL trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , grade &ge;3 pulmonary hemorrhage was observed in five patients (1.5 percent) receiving bevacizumab 7.5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      and 3 (0.9 percent) receiving 15.0",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      compared to two (0.6 percent) in the control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/55\">",
"       55",
"      </a>",
"      ]. The incidences of fatal PH in these groups were 1.2, 0.9, and 0.3 percent, respectively. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemoptysis has not been seen in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for advanced colorectal or breast cancer.",
"   </p>",
"   <p>",
"    Central tumor cavitation is common with the use of antiangiogenic agents, and is reported in 14 to 25 percent of cases of NSCLC during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/54,56\">",
"     54,56",
"    </a>",
"    ]. In a retrospective study of phase II trials, the presence of baseline cavitation but not central tumor location was associated with a higher risk of hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/54,57\">",
"     54,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the aforementioned data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is contraindicated in patients with squamous cell lung carcinoma and in any patient with hemoptysis (&gt;2.5 mL of blood) within three months. Additionally, some trials have also excluded patients with NSCLC from receiving bevacizumab if their tumors invade or abut major blood vessels, but this is not widely practiced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H525779238#H525779238\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Role of bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumor cavitation and bleeding complications have been observed rarely with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/58\">",
"     58",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/59\">",
"     59",
"    </a>",
"    ] for NSCLC. However, pulmonary hemorrhage has not been described in patients receiving either drug for other malignancies, and neither agent is approved for treatment of lung cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227422\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VEGF inhibitor needs to be discontinued in the setting of a severe bleed and supportive transfusions should be instituted. Given the short half life of antiangiogenic TKIs (unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ), cessation of the drug may rapidly reverse bleeding in this context.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    and anticoagulants should be discontinued, with careful consideration of the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio before resumption.",
"   </p>",
"   <p>",
"    Minor bleeding (eg, epistaxis) may be managed symptomatically with no discontinuation or only temporary cessation of the agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/41/1690?source=see_link\">",
"     \"Approach to the adult with epistaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchoscopic laser coagulation, electrocautery, argon plasma coagulation, haemostatic tamponade, and bronchial artery embolization may be useful in severe pulmonary hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Endobronchial irrigation with cold saline or epinephrine solution appears to have limited efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/62\">",
"     62",
"    </a>",
"    ]. Radiotherapy and surgery may be necessary to salvage some cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29558?source=see_link\">",
"     \"Overview of massive hemoptysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of intracranial hemorrhage should follow good clinical practice guidelines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227429\">",
"    <span class=\"h2\">",
"     Delayed wound healing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227437\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    has been associated with impaired wound healing in a variety of settings. This adverse effect is likely due to the critical role played by VEGF and angiogenesis during the early stages of wound healing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5177?source=see_link\">",
"     \"Wound healing and risk factors for non-healing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of wound healing problems with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was addressed in a meta-analysis comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (FU)-based chemotherapy with or without bevacizumab in patients who underwent surgery after beginning chemotherapy for mCRC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/63\">",
"     63",
"    </a>",
"    ]. Wound healing complications were observed in a higher fraction of those receiving bevacizumab (3.4 [1 of 29] versus 13 [10 of 75] percent), although this difference was not statistically significant (p&lt;0.28). Of the 10 patients who experienced wound healing complications after surgery with bevacizumab plus chemotherapy, the time interval between bevacizumab and surgery was 0 to 29 days in five patients, 30 to 59 days in five; no patient with more than 60 days between administration of bevacizumab and surgery had a wound complication.",
"   </p>",
"   <p>",
"    Based upon these data, and the long half life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (20 days), at least 28 days (preferably six to eight weeks) should elapse between surgery and last dose of bevacizumab, when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link&amp;anchor=H5842661#H5842661\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Issues related to bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety of surgery performed &ge;6 weeks after the last dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was confirmed in a retrospective study of three prospective trials of bevacizumab in patients with metastatic breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/64\">",
"     64",
"    </a>",
"    ]. There was a low risk of severe bleeding (0.1 to 0.9 percent) and a low risk of severe wound-healing complications (1.3 to 2.2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91044850\">",
"    <span class=\"h4\">",
"     Hepatic metastasectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired wound healing is especially germane to patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    prior to hepatic metastasectomy. Concerns about impaired wound healing and possibly impaired hepatic regeneration may affect the safety of metastasectomy, particularly if performed too soon after bevacizumab administration. It is generally recommended that six to eight weeks should elapse between the last dose of bevacizumab and elective hepatic resection. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=see_link\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91044857\">",
"    <span class=\"h4\">",
"     Recurrent glioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients treated for glioma, use of preoperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    also appears to be associated with delayed wound healing or wound dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In a series of 209 patients undergoing a second or third reoperation for recurrent glioblastoma, significantly more patients receiving preoperative bevacizumab developed wound healing complications than did non-bevacizumab-treated patients (35 versus 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/66\">",
"     66",
"    </a>",
"    ]. Wound healing complications developed in only 6 percent of those who only received bevacizumab postoperatively. The incidence of wound complications was most striking for the third craniotomy (44 percent) and for a shorter delay between bevacizumab and surgery. Based upon these results, the authors recommend that craniotomy not be performed until at least 28 days after the last dose of bevacizumab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91044864\">",
"    <span class=\"h4\">",
"     Portacath placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timing of administration also affects wound healing after chest wall port placement. In two studies, administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    within 10 to 14 days of chest wall portacath placement was associated with a higher incidence of wound healing complications and wound dehiscence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. When possible, bevacizumab should be held for at least two weeks after placement of a port. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91044871\">",
"    <span class=\"h4\">",
"     Tracheoesophageal fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of tracheoesophageal fistula has been reported in patients who were given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    with concomitant chemoradiotherapy or in the setting of prior thoracic irradiation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two independent phase II trials were discontinued for safety reasons after enrolling 29 patients with limited stage small cell lung cancer and five patients with advanced NSCLC, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/69\">",
"       69",
"      </a>",
"      ]. Among the 34 patients, there were four confirmed cases of tracheoesophageal fistula and one suspected clinically. In all cases, patients were receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      with concomitant chemoradiotherapy.",
"     </li>",
"     <li>",
"      There are at least two reported cases of tracheoesophageal fistula developing in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      who have a prior history of mediastinal irradiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/70,71\">",
"       70,71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    should be used cautiously in patients who have received prior mediastinal irradiation and avoided altogether in patients receiving concomitant chemoradiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227444\">",
"    <span class=\"h3\">",
"     Antiangiogenic TKIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired wound healing (and reopening of previously healed wounds) has also been observed following treatment with antiangiogenic TKIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/50,72-75\">",
"     50,72-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of all patients undergoing cytoreductive nephrectomy at MD Anderson over a seven-year period, use of presurgical systemic targeted therapy with a broad range of VEGF inhibitors including TKIs was predictive of having a complication &gt;90 days postoperatively, having multiple complications, and having wound complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study examining the use of neoadjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      as a means of selecting patients for cytoreductive nephrectomy, postoperative wound dehiscence resulted in discontinuation of postoperative bevacizumab in 3 of 50 evaluable patients, and a delay in reinstituting bevacizumab in two others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study comparing perioperative complications and surgical outcomes among 14 patients undergoing surgery after neoadjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      versus a control group of 73 consecutively treated patients who underwent surgery in the absence of prior systemic therapy observed less hemorrhagic and wound healing issues but a significant increase in incidence and severity of intraoperative adhesions during debulking nephrectomy in patients who received preoperative therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/50\">",
"       50",
"      </a>",
"      ]. The median time from TKI discontinuation to surgery was two weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some suggest that antiangiogenic TKIs be interrupted for at least one week (48 hours for agents with a short half-life such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    ) before surgery and not reinitiated until adequate wound healing has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/76\">",
"     76",
"    </a>",
"    ]. At many institutions, therapy with these agents is held for four weeks after major surgery and for at least two weeks after minor surgery, although there are no prospective data validating this approach. The decision to resume therapy following a major surgical intervention should be based upon clinical judgment of recovery from surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227451\">",
"    <span class=\"h2\">",
"     Intestinal perforation/fistula formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All VEGF targeted therapies can cause gastrointestinal perforation (GIP) and fistula formation, although this complication is best described in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . The mechanism by which these drugs contribute to GIP has not been proven, but proposed mechanisms include intestinal wall disruption (ulceration) in areas of tumor necrosis, disturbed platelet-endothelial cell homeostasis causing submucosal inflammation and subsequent ulcer formation, impaired healing of pathologic or surgical bowel injury, and mesenteric ischemia from thrombosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/77-79\">",
"     77-79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227458\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;GIP is an infrequent but potentially fatal toxicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . GIP may lead to peritonitis requiring emergency operative intervention, fistula formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/80\">",
"     80",
"    </a>",
"    ], or intraabdominal abscess. GIP has been reported in patients treated with bevacizumab for a variety of malignancies, but are most often described in the setting of metastatic colorectal cancer (mCRC) and epithelial ovarian cancer (EOC). Clinicians should maintain a high index of suspicion for GIP in patients who develop acute abdominal pain while receiving bevacizumab, even if they have no apparent risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435713276\">",
"    <span class=\"h4\">",
"     Diseases other than ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of GIP in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for conditions other than EOC has been addressed in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In randomized trials of chemotherapy with and without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in patients with mCRC and community-based cohort studies, the incidence of GIP in patients treated with bevacizumab has ranged from 1 to 4 percent. In a large community-based BRiTE observational cohort of patients treated with bevacizumab for mCRC, 37 of 1953 evaluable patients (1.9 percent) experienced GIP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/81\">",
"       81",
"      </a>",
"      ]. The majority of GIPs (26 of 37) occurred &le;6 months after starting bevacizumab (median, 3.35 months). In multivariate analysis, age &ge;65 years was significantly associated with lower GIP risk (1.1 versus 2.6 percent), while intact primary tumor (3 versus 1.7 percent) and prior adjuvant radiotherapy (3.4 versus 1.7 percent) were associated with increased risk. Neither a prior history of peptic ulcer disease nor use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or other NSAIDs was a risk factor. No cumulative risk was observed with duration of bevacizumab exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      are at risk, regardless of the type of malignancy; however, risk is variable. In a meta-analysis of over 12,000 patients from 17 randomized trials conducted in a variety of tumor types (six in mCRC, three NSCLC, two RCC, two pancreatic, four breast cancer, no trials in ovarian cancer), the incidence of GIP was approximately 1 percent overall regardless of tumor type, and the mortality rate was 22 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/82\">",
"       82",
"      </a>",
"      ]. The relative risk (RR) compared to controls not receiving bevacizumab was 2.14 (95% CI 1.19-3.85; p=0.011), and the risk was greater with higher bevacizumab doses (RRs for 5 and 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week were 2.67 [95% CI 1.14-6.26] and 1.61 [95% CI 0.76-3.38], respectively). Risks were highest in patients treated for CRC (relative risk 3.10, 95% CI 1.26-7.63) and RCC (relative risk 5.67, 0.66-48.42). Among patients with NSCLC, risk was not significantly elevated compared to controls (RR 1.55, 95% CI 0.37-6.59).",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although several risk factors have been described for GIP during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    treatment, bowel perforation may occur even in the absence of predisposing risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/83\">",
"     83",
"    </a>",
"    ], and it remains difficult to predict which patients will develop this complication. Many cases involve perforation of an in situ bowel primary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/84\">",
"     84",
"    </a>",
"    ]. However, surgical site complications can also occur at previously resected primary sites, often in the setting of previous irradiation or a prior anastomotic leak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/80,85,86\">",
"     80,85,86",
"    </a>",
"    ]. Perforation of an ileal neobladder has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GI tract ulcers, possibly caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , may predispose to perforation. One report described 18 patients with advanced colorectal cancer who participated in a phase III study and who were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , and bevacizumab with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    for mCRC who developed a GI ulcer (n=6), a GIP (n=8), or a perforated ulcer (n=4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/88\">",
"     88",
"    </a>",
"    ]. The occurrence of the perforations early in treatment, the established role of VEGF in ulcer healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/89\">",
"     89",
"    </a>",
"    ], and the inhibitory effect of bevacizumab on wound healing support the causative role of bevacizumab in ulcerogenesis.",
"   </p>",
"   <p>",
"    Accumulating data suggest a significantly increased risk of perforation in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for mCRC who subsequently undergo placement of an enteral stent. Thus, colonic stenting should not be performed in patients who are receiving bevacizumab. These data are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=see_link&amp;anchor=H9#H9\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\", section on 'Perforation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Another potential risk factor for GIP in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for treatment of glioma is use of concurrent high-dose glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of recurrent malignant gliomas\", section on 'Bevacizumab'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435713269\">",
"    <span class=\"h4\">",
"     Ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although GIP has been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for a variety of cancer primaries, it has attracted substantial attention in epithelial ovarian cancer (EOC) due to early reports noting high rates of GIP in these patients, and the common involvement of both the mesentery and the bowels in women with this disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11832?source=see_link&amp;anchor=H459225092#H459225092\">",
"     \"The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum\", section on 'Risk of gastrointestinal perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early studies suggested rates as high as 10 to 11 percent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early phase II study was terminated early when five GIPs were observed among 44 women (11 percent) treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      monotherapy for chemorefractory disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report of 112 patients with EOC who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      -containing regimens, 12 experienced a serious gastrointestinal event (10 [9 percent] had a GIP, and two a fistula) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/92\">",
"       92",
"      </a>",
"      ]. In this series the 30-day mortality rate was 50 percent, and 30 percent had died within one week of diagnosis. The only risk factor associated with",
"      <span class=\"nowrap\">",
"       GIP/fistula",
"      </span>",
"      formation was rectovaginal nodularity (odds ratio 3.64, 95% CI 1.1-12.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies lacked control groups for comparison, and they were conducted in populations of women with advanced, chemorefractory disease. It has been suggested that GIP may be more common in patients who are heavily pretreated with chemotherapy or who have diffuse peritoneal disease, significant small bowel disease, or bowel obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/77,93-95\">",
"     77,93-95",
"    </a>",
"    ], and that the exclusion of such patients from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    therapy results in a marked decrease in the rate of GIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/96\">",
"     96",
"    </a>",
"    ]. Lower rates of GIP and fistula formation have in fact been reported in subsequent phase III trials comparing bevacizumab-containing versus non-bevacizumab chemotherapy for women with EOC, possibly because women were excluded who have evidence of GI tract obstruction, and many of the trials were undertaken in the first-line setting, or for women with recurrent, platinum-sensitive disease rather than in heavily pretreated women with advanced disease. As examples (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link&amp;anchor=H284998595#H284998595\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Incorporation of angiogenesis inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/21/37209?source=see_link&amp;anchor=H1846264342#H1846264342\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\", section on 'Is there a role for bevacizumab?'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Gynecologic Oncology Group trial 218, in which 1873 previously untreated women with ovarian cancer were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , the risk of",
"      <span class=\"nowrap\">",
"       GIP/fistula",
"      </span>",
"      formation with and without bevacizumab was 3 versus 1 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, low rates of GIP were reported in the ICON7 trial of first line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/98\">",
"       98",
"      </a>",
"      ]. Among 1528 women enrolled to the trial, GIP occurred in 10 bevacizumab treated patients (versus 3 in the control group, 1.3 versus &lt;1 percent), and fistula",
"      <span class=\"nowrap\">",
"       formation/abscess",
"      </span>",
"      developed in 13 (versus 10 patients in the control group, 1.7 versus 1.3 percent).",
"     </li>",
"     <li>",
"      The role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      in recurrent platinum-sensitive EOC was studied in the OCEANS trial, in which 484 women were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      with or without bevacizumab [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/99\">",
"       99",
"      </a>",
"      ]. There were no reported cases of GIP, and rates of",
"      <span class=\"nowrap\">",
"       fistula/abscess",
"      </span>",
"      formation were also low in the bevacizumab group (4 versus 1 in the control group, 1.6 versus 0.4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H687211801\">",
"    <span class=\"h3\">",
"     Aflibercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer data are available for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    . In a phase III trial conducted in 1226 patients with mCRC, GIP occurred in 0.5 percent of patients treated with chemotherapy alone or without aflibercept [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/13\">",
"     13",
"    </a>",
"    ]. Rates of fistula formation of the GI tract with and without aflibercept were 1.1 versus 0.3 percent, and for fistulas from other than GI origin, rates were 0.3 versus 0.2 percent.",
"   </p>",
"   <p>",
"    The elimination half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    is shorter than for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (6 versus 20 days). There are no data addressing the safety of surgery in patients receiving treatment with this agent. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227465\">",
"    <span class=\"h3\">",
"     Antiangiogenic TKIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of GI perforation association with the antiangiogenic TKIs is unknown since only few cases have been reported in trials and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/100-104\">",
"     100-104",
"    </a>",
"    ]. One report described two patients with RCC that developed GIP during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , both of whom had received prior high dose interleukin (IL)-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/101\">",
"     101",
"    </a>",
"    ]. Moreover, both of these patients had undergone sunitinib therapy for an extended period of time (&gt;1 year). Intestinal GISTs have been reported to perforate during sunitinib therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/102\">",
"     102",
"    </a>",
"    ]. Case reports of GIP have also been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/103-105\">",
"     103-105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651227472\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to minimize the risk of GIP and fistula formation, at least 28 days (preferably six to eight weeks) should elapse between surgery and last dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , except in emergency situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/63\">",
"     63",
"    </a>",
"    ]. Given the shorter half life of the antiangiogenic TKIs, at least two weeks may suffice in this context. &nbsp;",
"   </p>",
"   <p>",
"    Any patient treated with an anti-VEGF agent, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , should be considered at risk for GIP. Mortality rates may be as high as 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/106\">",
"     106",
"    </a>",
"    ], and early detection might help reduce the morbidity and mortality of this complication.",
"   </p>",
"   <p>",
"    Perforation may be asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/107\">",
"     107",
"    </a>",
"    ], or it can present with abdominal pain due to peritoneal contamination, free air, hemoperitoneum, or intraabdominal abscess. Postoperative patients and those being treated for rectal cancer can present with a fistula or anastomotic leak. &nbsp;",
"   </p>",
"   <p>",
"    For all patients with new-onset abdominal pain while receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , the potential diagnosis of GIP should be evaluated urgently. The evaluation should include a complete history, physical examination (to rule out signs of peritonitis), and abdominal imaging (ie, radiograph to evaluate for free air, or non-contrasted computed tomography). Evaluation and diagnosis of suspected GIP are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link&amp;anchor=H20#H20\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Diffuse abdominal pain syndromes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41770?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\", section on 'Ancillary studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any case of GIP should result in the immediate and permanent discontinuation of VEGF-targeted therapy. Beyond that, there are no specific recommendations for management of documented GIP in patients receiving VEGF-targeted therapies. Patients with confirmed or highly suspected GIP whose overall condition is unstable secondary to the GIP should be considered for immediate surgical repair or diversion. Those who are more stable can be considered for less invasive management strategies such as bowel rest and broad-spectrum antibiotics with or without percutaneous drainage of concurrent abscesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. The timing of the presentation, the patient&rsquo;s overall condition, their goals and wishes, and overall prognosis are important factors in the decision to explore these patients surgically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557945051\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common side effect with all antiangiogenic TKIs, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    may enhance fatigue caused by other agents given in combination, eg, interferon or chemotherapy. While mild fatigue is common, severe fatigue is seldom seen. The mechanism of fatigue due to angiogenesis inhibitors is unclear. Contributing factors may be other drugs, hypothyroidism (especially with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ), anemia, dehydration (secondary to diarrhea, nausea or vomiting), and cardiac dysfunction, which should be addressed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=see_link\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1651229244\">",
"     'Thyroid dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Supportive care and psychostimulants may be employed. Severe fatigue may warrant dose modification or rarely, discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557944968\">",
"    <span class=\"h2\">",
"     Dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphonia has been observed with antiangiogenic TKIs, especially with newer more potent agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    , and the emerging agent tivozanib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. Dysphonia was also reported in 25 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    in a phase III trial conducted in mCRC (compared to 3 percent of the chemotherapy alone group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, dysphonia has not been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651228672\">",
"    <span class=\"h2\">",
"     Osteonecrosis of the jaw",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis of the jaw (ONJ) is defined by areas of tissue breakdown and exposure of bone in the maxillofacial region that fail to heal within eight&nbsp;weeks in a patient who has not received radiation of the jaws. &nbsp;",
"   </p>",
"   <p>",
"    There are isolated case reports of ONJ in patients treated with VEGF inhibitors, mostly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/111-118\">",
"     111-118",
"    </a>",
"    ]. However, the overall incidence appears to be low. One retrospective study analyzed 3560 patients receiving bevacizumab-containing therapy for advanced breast cancer in two double-blind, randomized trials and a large, non-randomized safety study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/119\">",
"     119",
"    </a>",
"    ]. ONJ occurred in 0.3 percent of patients receiving bevacizumab in the blinded phase of the two randomized trials and in 0.4 percent of patients in the single-arm study.",
"   </p>",
"   <p>",
"    However, there is a higher incidence among patients with bone metastases who are also receiving therapy with an osteoclast inhibitor for prevention of skeletal related events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/119-122\">",
"     119-122",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .) As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the above mentioned retrospective study of 3560 patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      -containing therapy for advanced breast cancer in two double-blind, randomized trials and a large, non-randomized safety study, there was a trend towards increased ONJ in those who received bisphosphonates (0.9 versus 0.2 percent) in the analysis of the randomized trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, 11 of 60 (18.3 percent) patients with metastatic castration resistant prostate cancer (mCRPC) administered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      with concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      developed ONJ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/120\">",
"       120",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An increased risk of ONJ has also been reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    in conjunction with a bisphosphonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/121,123\">",
"     121,123",
"    </a>",
"    ]. In a preliminary report of a retrospective review of 21 patients who received sunitinib with a concomitant bisphosphonate, five (21 percent) developed ONJ, two of which were attributed to recent dental work [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609118754\">",
"    <span class=\"h3\">",
"     Prevention and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures consist of maintaining oral hygiene, pretreatment dental examination, and avoiding invasive dental procedures prior to and during therapy. Pretreatment dental evaluation is important in patients receiving therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Established ONJ may be managed by conservative or surgical measures based on severity of symptoms. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H8702257#H8702257\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=see_link&amp;anchor=H1928489#H1928489\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651228679\">",
"    <span class=\"h2\">",
"     Reversible posterior leukoencephalopathy and brain capillary leak syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinical radiographic syndrome of heterogeneous etiologies that are grouped together because of similar findings on neuroimaging studies. It is also often referred to as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Posterior reversible encephalopathy syndrome (PRES)",
"     </li>",
"     <li>",
"      Reversible posterior cerebral edema syndrome",
"     </li>",
"     <li>",
"      Posterior leukoencephalopathy syndrome",
"     </li>",
"     <li>",
"      Hyperperfusion encephalopathy",
"     </li>",
"     <li>",
"      Brain capillary leak syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these names is completely satisfactory; the syndrome is not always reversible, and it is often not confined to either the white matter or the posterior regions of the brain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link&amp;anchor=H1#H1\">",
"     \"Reversible posterior leukoencephalopathy syndrome\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of RPLS remains unclear, but it appears to be related to disordered cerebral autoregulation and endothelial dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link&amp;anchor=H3#H3\">",
"     \"Reversible posterior leukoencephalopathy syndrome\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical syndrome of reversible posterior leukoencephalopathy syndrome (RPLS) is characterized by headaches, altered consciousness, visual disturbances, and seizures; hypertension is frequent but not invariable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link&amp;anchor=H13#H13\">",
"     \"Reversible posterior leukoencephalopathy syndrome\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A wide variety of medical conditions have been implicated as causes of RPLS (",
"    <a class=\"graphic graphic_table graphicRef51758 \" href=\"mobipreview.htm?21/50/22316\">",
"     table 1",
"    </a>",
"    ), including rapidly developing, fluctuating, or intermittent hypertension, and therapy with a VEGF-targeted agent (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/124-134\">",
"     124-134",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link&amp;anchor=H9#H9\">",
"     \"Reversible posterior leukoencephalopathy syndrome\", section on 'Associated conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609118768\">",
"    <span class=\"h3\">",
"     Prevention and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stringent control of blood pressure is critical to avert this rare complication. In suspected cases of RPLS, discontinuation of the offending agent is essential. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=see_link&amp;anchor=H17#H17\">",
"     \"Reversible posterior leukoencephalopathy syndrome\", section on 'Prevention and treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651228686\">",
"    <span class=\"h2\">",
"     Microangiopathic hemolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    has been associated with microangiopathic hemolysis in rare reports, sometimes in associated with a thrombotic thrombocytopenia",
"    <span class=\"nowrap\">",
"     purpura/hemolytic",
"    </span>",
"    uremic syndrome",
"    <span class=\"nowrap\">",
"     (TTP/HUS)-type",
"    </span>",
"    picture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/132,135-137\">",
"     132,135-137",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    alone and antiangiogenic TKIs have not been reported to be associated with microangiopathic hemolysis. However, the combination of antiangiogenic TKIs plus bevacizumab appears to exacerbate the risk of this potentially life-threatening toxicity; because of this, they should not be co-administered off-protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients present with hemolysis with or without a thrombotic angiopathy; hypertension is present in most but not all cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Clinical and laboratory manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to withdrawal of the offending agent, control of hypertension and plasmapheresis constitute recognized therapeutic interventions. A single case report describes successful recovery after plasmapheresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/135\">",
"     135",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=see_link&amp;anchor=H43#H43\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Drug-induced TTP-HUS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229236\">",
"    <span class=\"h1\">",
"     CLASS EFFECTS OF VEGF RECEPTOR TKIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229244\">",
"    <span class=\"h2\">",
"     Thyroid dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid dysfunction is frequently observed in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    . Typically this has been manifested by hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/139-141\">",
"     139-141",
"    </a>",
"    ]. In one series, 15 of 42 euthyroid patients with intact thyroid glands (36 percent) became hypothyroid (as defined as a persistently elevated level of thyroid stimulating hormone [TSH]) while receiving sunitinib for advanced GIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/140\">",
"     140",
"    </a>",
"    ]. The risk increased with longer duration of therapy (18, 29, and 90 percent in patients treated for 36, 52, and 96 weeks, respectively). The mean time to development of hypothyroidism was 50 weeks.",
"   </p>",
"   <p>",
"    The mechanism by which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    causes hypothyroidism has yet to be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/142\">",
"     142",
"    </a>",
"    ]. Inhibition of iodine uptake may be responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/143\">",
"     143",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p>",
"    However, several reports have described transient thyrotoxicosis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    treatment in patients with metastatic RCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/144-146\">",
"     144-146",
"    </a>",
"    ]. In one report, six patients developed thyrotoxicosis after starting treatment with sunitinib, and four later became hypothyroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/144\">",
"     144",
"    </a>",
"    ]. Some of these patients appeared to have a destructive thyroiditis, characterized by transient thyrotoxicosis (with low radioiodine uptake, which distinguishes it from Graves' disease) followed by hypothyroidism associated with atrophy of thyroid follicular cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/144,145\">",
"     144,145",
"    </a>",
"    ]. However, a case of lymphocytic thyroiditis accompanied by transient thyrotoxicosis has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/147\">",
"     147",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43830?source=see_link\">",
"     \"Overview of thyroiditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4103?source=see_link&amp;anchor=H12#H12\">",
"     \"Disorders that cause hyperthyroidism\", section on 'Thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroid dysfunction also occurs in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    for metastatic RCC, but this appears to be less frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/141,148-151\">",
"     141,148-151",
"    </a>",
"    ]. In an analysis of thyroid function in 39 patients, hypothyroidism was seen in seven (18 percent) and hyperthyroidism in one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/148\">",
"     148",
"    </a>",
"    ]. Two of the hypothyroid patients (5 percent of the total) were symptomatic and required thyroid replacement therapy. Others report a similar frequency of thyroid hormone replacement therapy among patients taking sorafenib (6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothyroidism is also reported for patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    , and hence appears to be a class-effect of these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229251\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high prevalence of hypothyroidism, regular surveillance of TSH levels is warranted during therapy with antiangiogenic TKIs, more frequently in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    . We suggest that thyroid function be evaluated at baseline and monitored every 6 to 12 weeks thereafter and earlier if dictated by symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=see_link\">",
"     \"Diagnosis of and screening for hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroid hormone supplementation should be given to symptomatic patients with hypothyroidism. Discontinuations and dose modifications of the VEGF receptor TKI is usually not necessary.",
"   </p>",
"   <p>",
"    Transient thyrotoxicosis may be seen preceding hypothyroidism and there are no reports suggesting that therapeutic intervention is warranted. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229258\">",
"    <span class=\"h2\">",
"     Myelosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myelosuppression has been observed more commonly when utilizing antiangiogenic TKIs that more potently target Flt3 (FMS-related tyrosine kinase 3 receptor) and KIT, which are required for hematopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/154\">",
"     154",
"    </a>",
"    ]. When comparing across different trials, sunitinib and sorafenib appear more myelosuppressive than more selective TKIs such as pazopanib, axitinib, and cabozantinib. Indeed, the combination of sunitinib with relatively non-myelosuppressive chemotherapy regimens, eg, carboplatin plus paclitaxel, has appeared prohibitively myelosuppressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/155\">",
"     155",
"    </a>",
"    ]. Moreover, thrombocytopenia and leukopenia induced by sunitinib appeared to be Flt-3 genotype and CYP1A polymorphism dependent, respectively, in retrospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/156,157\">",
"     156,157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is not known to cause significant myelosuppression.",
"   </p>",
"   <p>",
"    Recurring grade 3 or 4 neutropenia or thrombocytopenia (",
"    <a class=\"graphic graphic_table graphicRef64984 \" href=\"mobipreview.htm?25/21/25948\">",
"     table 2",
"    </a>",
"    ) persisting for at least five days",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    febrile",
"    <span class=\"nowrap\">",
"     neutropenia/bleeding",
"    </span>",
"    require dose alterations. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229272\">",
"    <span class=\"h2\">",
"     Stomatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomatitis may be seen with all the antiangiogenic TKIs. Rates are variable, but it appears to be more common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (29 to 48 percent),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (25 to 28 percent), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    (51 percent) than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    (4 to 12 percent) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    (15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/109,158,159\">",
"     109,158,159",
"    </a>",
"    ]. Symptoms of oral pain, dysgeusia, dysphagia, and aphthous ulcers may occur rather than conventional oral mucositis. The mechanism is unclear but may be related to poor healing of microtrauma (similar to the proposed mechanism for hand-foot skin reaction). (See",
"    <a class=\"local\" href=\"#H1651229286\">",
"     'Cutaneous toxicity'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=see_link&amp;anchor=H4#H4\">",
"     \"Oral toxicity associated with chemotherapy\", section on 'Etiology and risk factors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In a phase III trial of FOLFIRI with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"     aflibercept",
"    </a>",
"    in mCRC, rates of mucositis were higher in the combined therapy arm (55 versus 35 percent for all-grade, and 14 versus 5 percent for severe) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/13\">",
"     13",
"    </a>",
"    ], suggesting that anti-VEGF agents may exacerbate the risk of mucositis from chemotherapy; however, this has not been seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229279\">",
"    <span class=\"h2\">",
"     Gastrointestinal toxicities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea, nausea, and emesis have been observed with all antiangiogenic TKIs and are generally mild. &nbsp;",
"   </p>",
"   <p>",
"    In clinical trials, diarrhea of any grade has been reported in 30 to 79 percent of patients (highest rates with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    ), with severe diarrhea (grade 3 or 4) in 3 to 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/14,30,109,160-164\">",
"     14,30,109,160-164",
"    </a>",
"    ]. Vandetanib is a moderately potent EGFR (epidermal growth factor) receptor inhibitor in addition to being a VEGFR inhibitor, which explains the somewhat higher incidence of diarrhea associated with this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/160,161\">",
"     160,161",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical trials, nausea of any grade has been reported in 23 to 58 percent of treated patients, and rates are highest in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"     cabozantinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/158,165,166\">",
"     158,165,166",
"    </a>",
"    ]. Vomiting of any grade has been reported in 10 to 48 percent of treated patients; rates are lowest with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and highest with sunitinib and cabozantinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/158,165,166\">",
"     158,165,166",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609118804\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic management of grade 1 or 2 diarrhea with an oral antidiarrheal agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    , generally suffices. Treatment interruption is necessary for grade 3 or 4 diarrhea, and dose modifications may be necessary to control diarrhea if the drug is continued.",
"   </p>",
"   <p>",
"    Nausea and vomiting is rarely severe and can usually be controlled with oral antiemetics. However, caution should be exercised in combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    with serotonin antagonists such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    , due to the potential for QTc interval prolongation and torsade de pointes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H1063204941#H1063204941\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Prolongation of the QTc interval and cardiac arrhythmias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link&amp;anchor=H2662553#H2662553\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'EKG interval changes and cardiac arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229286\">",
"    <span class=\"h2\">",
"     Cutaneous toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A range of cutaneous toxicities has been reported in patients receiving antiangiogenic TKIs (",
"    <a class=\"graphic graphic_table graphicRef74634 \" href=\"mobipreview.htm?7/45/7900\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H7#H7\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Small molecule kinase signal transduction inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hand-foot skin reaction (HFSR) is a common cutaneous manifestation of toxicity with oral antiangiogenic TKIs. HFSRs appear to be more common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , and more common with these drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    , as compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/14,109,167\">",
"     14,109,167",
"    </a>",
"    ]. Interestingly, as has been seen with hypertension, an association between skin toxicity and improved outcomes has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/168\">",
"     168",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H7#H7\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Small molecule kinase signal transduction inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H30695629#H30695629\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Association with antitumor efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple case reports have also identified an increased risk of keratoacanthomas and squamous cell carcinoma in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H11#H11\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Squamoproliferative lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     Vandetanib",
"    </a>",
"    also inhibits the epidermal growth factor receptor (EGFR) and has been associated with a generalized maculopapular erythematous acneiform rash that is typical of other EGFR inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H2#H2\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'EGFR signal transduction inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H22183968#H22183968\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Vandetanib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609119004\">",
"    <span class=\"h3\">",
"     Prevention and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA-approved manufacturer&rsquo;s product labeling provides suggested dose modifications for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    based upon the grade of HFSR (",
"    <a class=\"graphic graphic_table graphicRef82460 \" href=\"mobipreview.htm?9/56/10123\">",
"     table 4",
"    </a>",
"    ) during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/169\">",
"     169",
"    </a>",
"    ]. Guidelines are not available for the other agents.",
"   </p>",
"   <p>",
"    Prevention and management strategies for HFSR in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    are also available from an international consensus group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/76\">",
"     76",
"    </a>",
"    ]. This subject is presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H10#H10\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Hand-foot skin reaction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention and management strategies for the acneiform eruption in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    and other EGFR inhibitors are provided in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=see_link&amp;anchor=H195039192#H195039192\">",
"     \"Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=see_link&amp;anchor=H52639361#H52639361\">",
"     \"Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive guidelines for continuing versus discontinuing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    in patients who develop squamoproliferative lesions while on sorafenib or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    therapy have not been established. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H11#H11\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Squamoproliferative lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557944336\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe and occasionally fatal hepatotoxicity has been observed in clinical studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    , and especially",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    . &nbsp;",
"    <br/>",
"    <br/>",
"    Although they have been associated with mild increases in transaminases,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"     vandetanib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    have not been associated with severe hepatic toxicities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557944363\">",
"    <span class=\"h3\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in the uridine diphospho-glucuronosyltransferase 1A1 (UGT 1A1) enzyme that cause Gilbert's syndrome (the UGT1A1*28 allele) may be associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    -induced hyperbilirubinemia. Isolated hyperbilirubinemia in these patients may represent a benign manifestation of Gilbert's syndrome, and continuation of pazopanib monotherapy is reasonable in this setting. This subject is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H217131874#H217131874\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Pazopanib'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For patients with pre-existing moderate hepatic impairment, the US FDA-approved manufacturer&rsquo;s package insert recommends that starting doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    be reduced and that the drug be avoided in patients with pre-existing severe hepatic impairment, defined as total bilirubin &gt;3 times the upper limit of normal (ULN) with any level of",
"    <span class=\"nowrap\">",
"     ALT/AST",
"    </span>",
"    elevation. During therapy, close monitoring of LFTs is recommended, particularly within the first nine weeks of treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H217131874#H217131874\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Pazopanib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557944370\">",
"    <span class=\"h3\">",
"     Ponatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hepatotoxicity, liver failure, and death have also been reported in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    treated patients. As hepatic elimination is a major route of excretion, hepatic impairment may result in increased ponatinib exposure. The FDA-approved manufacturer&rsquo;s package insert recommends avoiding use of the drug in patients with moderate to severe (Child-Pugh B or C, (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 5",
"    </a>",
"    )) hepatic impairment unless the benefit outweighs the possible risk of ponatinib overexposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H1157198779#H1157198779\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Ponatinib'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557944377\">",
"    <span class=\"h3\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    -induced hepatitis is characterized by a hepatocellular pattern of liver damage with significant increases of transaminases, which may result in hepatic failure and death. Increases in bilirubin and INR may also occur. The FDA-approved manufacturer&rsquo;s package insert recommends that the drug be discontinued in case of significantly increased transaminases without alternative explanation such as viral hepatitis or progressing underlying malignancy. There are conflicting data on the need for dose reduction in patients with preexisting liver dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H48#H48\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Sorafenib'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557944384\">",
"    <span class=\"h3\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially fatal hepatotoxicity has been observed in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    . The FDA-approved manufacturer&rsquo;s package insert recommends treatment interruption for bilirubin levels &gt;3X ULN or",
"    <span class=\"nowrap\">",
"     AST/ALT",
"    </span>",
"    &gt;5X ULN, and discontinuation of sunitinib if there is no resolution or if patients subsequently experience severe changes in liver function tests (LFTs) or have other signs and symptoms of liver failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H204884583#H204884583\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Sunitinib'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184151441\">",
"    <span class=\"h3\">",
"     Monitoring and mangement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with any of these agents should have a baseline evaluation of LFTs and periodic reevaluation (at least monthly) during therapy. For patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    (particularly if they are elderly), we monitor LFTs at two, four, six, and eight weeks, then every eight weeks. Treatment should be interrupted or discontinued if evidence of toxicity is observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229307\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229315\">",
"    <span class=\"h3\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations of the pancreatic enzymes lipase and amylase are frequently reported in patients treated with antiangiogenic TKIs, although overt pancreatitis is rare, with the possible exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/162,170,171\">",
"     162,170,171",
"    </a>",
"    ]. In a phase II trial of ponatinib in 81 patients with refractory chronic myelogenous leukemia, pancreatitis developed in 11 (14 percent) and was severe (grade 3 or worse) in four (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/171\">",
"     171",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We continue therapy with the TKI unless patients develop clinical pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229323\">",
"    <span class=\"h3\">",
"     Glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood glucose levels may be reduced in patients who are treated with antiangiogenic TKIs for a variety of malignancies. In a retrospective series of 19 type II diabetic patients whose blood glucose was monitored at baseline and during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    , blood glucose levels fell from 149",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at baseline to 117",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at four weeks (8.3 to 6.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/172\">",
"     172",
"    </a>",
"    ]. In contrast, blood glucose levels fell only minimally in nine nondiabetic patients (106 to 95",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.89 to 5.26",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    who were similarly monitored. No serious episodes of hypoglycemia were reported.",
"   </p>",
"   <p>",
"    However, other data suggest that this complication is not related to VEGFR inhibition and that declines in blood glucose can be seen both in diabetic and nondiabetic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/173\">",
"     173",
"    </a>",
"    ]. In this retrospective review of diabetic (n=17) and non-diabetic (n=61) patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , all four drugs were associated with significant mean declines in blood glucose, which were greatest (52",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    with dasatinib. The magnitude of decline in blood glucose was similar in diabetic and non-diabetic patients. The authors concluded that inhibition of KIT or platelet derived growth factor receptor beta (PDGFRB), common target kinases among the four drugs, might be responsible for this effect. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609119062\">",
"    <span class=\"h4\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood glucose levels should be monitored in diabetic patients who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , and antidiabetic medications adjusted if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229330\">",
"    <span class=\"h1\">",
"     AGENT SPECIFIC EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229338\">",
"    <span class=\"h2\">",
"     Bevacizumab",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229346\">",
"    <span class=\"h3\">",
"     Nasal septal perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal septal perforation has been observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    administered in combination with chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/174,175\">",
"     174,175",
"    </a>",
"    ].The US FDA recognized this complication in 2006 after seven postmarketing reports became available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/176\">",
"     176",
"    </a>",
"    ]. However, this is a rare complication. To date, only 18 cases have been published in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/177\">",
"     177",
"    </a>",
"    ]. Although the data are sparse, some groups of patients may be at a higher risk of this complication. The perforations occurred in combination with taxanes and higher doses of bevacizumab (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once every three weeks) in many cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/174\">",
"     174",
"    </a>",
"    ] , but they have also been reported in patients treated with bevacizumab and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    -based chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/175\">",
"     175",
"    </a>",
"    ]. The overall risk in this series of 100 patients treated for mCRC was only 1 percent.",
"   </p>",
"   <p>",
"    The mechanism may be related to underlying mucositis, delayed tissue repair, and additive or synergistic antiangiogenic activity of taxanes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609119069\">",
"    <span class=\"h4\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients develop this complication, other potential causes of perforation should be excluded, even if the patient is receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . The evaluation should include inspection of the nasal septum for evidence of infection and obtaining local cultures to exclude other causes of perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/178\">",
"     178",
"    </a>",
"    ]. Septal perforation is often seen in those who use intranasal cocaine. It may also result from septal surgery, atrophic rhinitis, granulomatosis with polyangiitis (Wegener's), and several other disorders (",
"    <a class=\"graphic graphic_table graphicRef64345 \" href=\"mobipreview.htm?33/9/33947\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiologies of nasal symptoms: An overview\", section on 'Disorders affecting the septum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with a nasal septal perforation should be referred to an otolaryngologist for evaluation and management. Most perforations, particularly those that are posterior and asymptomatic, can be medically managed with frequent irrigation of the area with saline, and application of lubricant gels and other supportive deal with epistaxis or pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/177\">",
"     177",
"    </a>",
"    ]. In most instances, surgical repair is not undertaken, but closing the perforation with a bridge flap, or more commonly, a button, is an option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/179\">",
"     179",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision as to whether to continue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in a patient who has developed a nasal septal perforation must be individualized. In the published literature, a few patients continued with bevacizumab and seemed to do fine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/174,180,181\">",
"     174,180,181",
"    </a>",
"    ]. However, given the propensity of bevacizumab to delay wound healing, it seems prudent to wait for some evidence of perforation stability and healing prior to continuing the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/177\">",
"     177",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557944583\">",
"    <span class=\"h2\">",
"     Sorafenib and muscle wasting/sarcopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer cachexia is characterized by diminished nutrient intake and progressive tissue depletion, both of which lead to weight loss. A disproportionate and excessive loss of lean body mass is the hallmark of cancer cachexia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and pathogenesis of cancer cachexia\", section on 'Changes in body composition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sarcopenia (skeletal muscle wasting) may also be an adverse effect of treatment with the antiangiogenic TKIs, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sarcopenia was linked to dose-limiting toxicities in a phase I study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      in RCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/182\">",
"       182",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subset analysis of 80 patients with RCC who were treated in the TARGET trial, body weight was measured and skeletal muscle mass was serially assessed by CT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/183\">",
"       183",
"      </a>",
"      ]. At six months,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      therapy was associated with a statistically significant decrease in total body weight and muscle mass compared to placebo (-2.1 versus +0.8 kg and -7.4 versus -3.1 cm",
"      <sup>",
"       2",
"      </sup>",
"      , respectively). The loss in weight and muscle mass in patients treated with sorafenib was progressive during treatment from 6 to 12 months.",
"     </li>",
"     <li>",
"      An associated between sarcopenia,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      exposure, and dose limiting toxicity within the first month of treatment has also been seen in patients receiving sorafenib for HCC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/184\">",
"       184",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The loss of muscle mass appears to be additive to that caused by advanced cancer and may contribute to asthenia and fatigue.",
"   </p>",
"   <p>",
"    Whether or not sarcopenia represents a class effect of VEGF-targeted therapy is unclear. At least some data reports muscle loss in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    -containing chemotherapy for metastatic cancer, but there was no control group in either study, and the effects could have been attributable to the chemotherapy that was given in conjunction with bevacizumab or progression of the cancer itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/54/43882/abstract/185,186\">",
"     185,186",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1651229780\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiangiogenic agents have unique toxicities that differ from those of traditional chemotherapy. Antiangiogenic agents available in the clinic include the vascular endothelial growth factor (VEGF) ligand inhibiting agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      ) and tyrosine kinase inhibitors (TKIs) that target angiogenesis (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"       vandetanib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/22/7526?source=see_link\">",
"       cabozantinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"       axitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       regorafenib",
"      </a>",
"      ). Toxicities of antiangiogenic agents may be classified as VEGF class-specific, drug class-specific, or agent-specific. (See",
"      <a class=\"local\" href=\"#H1651224889\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many of the adverse effects seen with angiogenesis inhibitors, particularly the cardiovascular effects and hemorrhage, are serious and potentially fatal. (See",
"      <a class=\"local\" href=\"#H89432012\">",
"       'Risk of fatality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful selection of patients for therapy with angiogenesis inhibitors (ie, reasonable performance status, controlled blood pressure, and lack of serious cardiovascular events within six months) as well as close monitoring and prompt intervention are necessary to alleviate the risks posed by these toxicities.",
"     </li>",
"     <li>",
"      All VEGF-targeted agents cause proteinuria, which is rarely nephrotic range (&gt;3.5",
"      <span class=\"nowrap\">",
"       g/24",
"      </span>",
"      hours), and even more rarely, associated with the nephrotic syndrome. The implications of asymptomatic proteinuria from VEGF inhibitors are unknown and it is possible that the vast majority of cases have no clinical consequences. However, baseline and periodic urinalysis should be performed during treatment with all of these agents. (See",
"      <a class=\"local\" href=\"#H1651225341\">",
"       'Proteinuria/nephrotic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All VEGF-targeted agents have been associated with an increased risk of hemorrhage. This is most commonly grade 1 epistaxis, serious, and in some cases, fatal hemorrhagic events, including hemoptysis (particularly in patients with squamous cell lung cancer), gastrointestinal bleeding, hematemesis, intracerebral hemorrhage, epistaxis, and vaginal bleeding, have occurred (risk of major bleeding approximately 2 to 3 percent). (See",
"      <a class=\"local\" href=\"#H1651227378\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because of the risk of massive hemoptysis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      is contraindicated in patients with squamous cell lung carcinoma and in any patient with hemoptysis (&gt;2.5 mL of blood) within three months. (See",
"      <a class=\"local\" href=\"#H1651227415\">",
"       'Pulmonary hemorrhage and cavitation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The risk of intracranial bleeding is low, even in patients with nonhemorrhagic brain metastases and recurrent gliomas. Patients with a history of treated nonhemorrhagic brain metastases or a recurrent primary brain tumor need not be excluded from systemic therapy with a VEGF inhibitor. (See",
"      <a class=\"local\" href=\"#H1651227407\">",
"       'Intracranial bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      and antiangiogenic TKIs have been associated with impaired wound healing in a variety of settings. At least 28 days (preferably six to eight weeks) should elapse between surgery and last dose of bevacizumab, except when clinically necessary. (See",
"      <a class=\"local\" href=\"#H1651227437\">",
"       'Bevacizumab'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If the clinical situation permits, antiangiogenic TKIs should be interrupted for at least one week before surgery and not reinitiated until adequate wound healing has occurred, usually at least two to four weeks after major surgery. (See",
"      <a class=\"local\" href=\"#H1651227444\">",
"       'Antiangiogenic TKIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although best described with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , all VEGF targeted therapies can cause gastrointestinal perforation (GIP) leading to peritonitis, fistula formation, or intraabdominal abscess. Clinicians should maintain a high index of suspicion for GIP in patients who develop acute abdominal pain while receiving bevacizumab, even if they have no apparent risk factors. (See",
"      <a class=\"local\" href=\"#H1651227451\">",
"       'Intestinal perforation/fistula formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are isolated case reports of osteonecrosis of the jaw in patients treated with VEGF inhibitors, mostly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , but the overall incidence appears to be low. (See",
"      <a class=\"local\" href=\"#H1651228672\">",
"       'Osteonecrosis of the jaw'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiangiogenic therapy can cause reversible posterior leukoencephalopathy syndrome (RPLS), a clinical-radiographic syndrome thought due to brain capillary leak and characterized by headaches, altered consciousness, visual disturbances, and seizures with or without hypertension. (See",
"      <a class=\"local\" href=\"#H1651228679\">",
"       'Reversible posterior leukoencephalopathy and brain capillary leak syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fatigue is a common side effect with all VEGF-targeted agents, but is usually mild. (See",
"      <a class=\"local\" href=\"#H1557945051\">",
"       'Fatigue'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dysphonia has been reported with antiangiogenic TKIs and with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/28/37312?source=see_link\">",
"       aflibercept",
"      </a>",
"      but not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1557944968\">",
"       'Dysphonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thyroid dysfunction is a class effect of the antiangiogenic TKIs, though it is most frequent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1651229244\">",
"       'Thyroid dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild myelosuppression is also a class effect of the antiangiogenic TKIs, and seen most often with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      , because they target Flt3 and KIT, which are required for hematopoiesis. (See",
"      <a class=\"local\" href=\"#H1651229258\">",
"       'Myelosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stomatitis may be seen with all the antiangiogenic TKIs, but it appears to be most common with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1651229272\">",
"       'Stomatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diarrhea, nausea, and emesis have been observed with all antiangiogenic TKIs; rates of diarrhea are higher with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"       vandetanib",
"      </a>",
"      , probably because it also inhibits the epidermal growth factor receptor (EGFR). (See",
"      <a class=\"local\" href=\"#H1651229279\">",
"       'Gastrointestinal toxicities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous toxicity with the antiangiogenic TKIs includes hand-foot skin reaction (especially with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      ), an increased risk of keratoacanthomas and squamous cell carcinoma with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      or sorafenib, and an acneiform rash with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/42/17063?source=see_link\">",
"       vandetanib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1651229286\">",
"       'Cutaneous toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       Sunitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      , and especially",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"       pazopanib",
"      </a>",
"      have been associated with severe and occasionally fatal hepatic toxicities. Patients treated with these agents should have a baseline evaluation of liver function tests (LFTs) and periodic reevaluation (at least monthly) during therapy. (See",
"      <a class=\"local\" href=\"#H1557944336\">",
"       'Hepatotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevations of the pancreatic enzymes lipase and amylase have been reported with antiangiogenic TKIs, although overt pancreatitis is rare, with the possible exception of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1651229315\">",
"       'Pancreatitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      has been associated in rare cases with nasal septal perforation. (See",
"      <a class=\"local\" href=\"#H1651229346\">",
"       'Nasal septal perforation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sarcopenia (skeletal muscle wasting) has been associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1557944583\">",
"       'Sorafenib and muscle wasting/sarcopenia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/1\">",
"      Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency website is file://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&amp;mid= (Accessed on December 13, 2012).",
"    </li>",
"    <li>",
"     Tabernero J VCE, Lakomy R, et al. Results from VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC). ESMO Congress November 2011, Late Breaking Abstract #6, Stockholm, Sweden.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/4\">",
"      Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/5\">",
"      Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012; 30:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/6\">",
"      Sivendran S, Liu Z, Portas LJ Jr, et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012; 38:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/7\">",
"      Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 2004; 10:4258s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/8\">",
"      Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/9\">",
"      Costero O, Picazo ML, Zamora P, et al. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 2010; 25:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/10\">",
"      Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010; 46:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/11\">",
"      Tomita Y, Uemura H, Fujimoto H, et al. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 2011; 47:2592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/12\">",
"      Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/13\">",
"      Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30:3499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/14\">",
"      Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/15\">",
"      Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/16\">",
"      Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009; 48:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/17\">",
"      Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm 2009; 66:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/18\">",
"      Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/19\">",
"      Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/20\">",
"      Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/21\">",
"      Boll&eacute;e G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009; 24:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/22\">",
"      George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49:e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/23\">",
"      Eremina V, Quaggin SE. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004; 13:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/24\">",
"      Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999; 104:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/25\">",
"      Yeh J, Frieze D, Martins R, Carr L. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother 2010; 44:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/26\">",
"      Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27:4462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/27\">",
"      Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 2008; 100:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/28\">",
"      Halimi JM, Azizi M, Bobrie G, et al. [Vascular and renal effects of anti-angiogenic therapy]. Nephrol Ther 2008; 4:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/29\">",
"      Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/30\">",
"      Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/31\">",
"      Tam BY, Wei K, Rudge JS, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006; 12:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/32\">",
"      Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 2008; 26:4047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/33\">",
"      Harshman LC, Kuo CJ, Wong BY, et al. Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. Cancer Invest 2009; 27:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/34\">",
"      van der Veldt AA, Boven E, Vroling L, et al. Sunitinib-induced hemoglobin changes are related to the dosing schedule. J Clin Oncol 2009; 27:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/35\">",
"      Alexandre I, Billemont B, Meric JB, et al. Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. J Clin Oncol 2009; 27:472.",
"     </a>",
"    </li>",
"    <li>",
"     Harshman LC KC, Srinivas S. Bevacizumab-associated erythrocytosis in metastatic renal cell carcinoma. J Clin Oncol 26: 2008 (May 20 suppl; abstr 16096).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/37\">",
"      Hang XF, Xu WS, Wang JX, et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011; 67:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/38\">",
"      Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010; 79:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/39\">",
"      Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/40\">",
"      Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009; 14:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/41\">",
"      Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/42\">",
"      Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/43\">",
"      Besse B, Lasserre SF, Compton P, et al. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/44\">",
"      Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27:5255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/45\">",
"      Crin&ograve; L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/46\">",
"      Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 2008; 10:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/47\">",
"      Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/48\">",
"      Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/49\">",
"      Norden AD, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012; 106:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/50\">",
"      Harshman LC, Yu RJ, Allen GI, et al. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol 2013; 31:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/51\">",
"      Sandler A, Hirsh V, Reck M, et al. An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer 2012; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/52\">",
"      Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008; 53:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/53\">",
"      Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/54\">",
"      Crabb SJ, Patsios D, Sauerbrei E, et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 2009; 27:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/55\">",
"      Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/56\">",
"      Marom EM, Martinez CH, Truong MT, et al. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 2008; 3:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/57\">",
"      Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009; 27:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/58\">",
"      Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/59\">",
"      Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:4274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/60\">",
"      Reck M, Barlesi F, Crin&ograve; L, et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 2012; 23:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/61\">",
"      Valipour A, Kreuzer A, Koller H, et al. Bronchoscopy-guided topical hemostatic tamponade therapy for the management of life-threatening hemoptysis. Chest 2005; 127:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/62\">",
"      Kvale PA, Selecky PA, Prakash UB, American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:368S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/63\">",
"      Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/64\">",
"      Cort&eacute;s J, Caralt M, Delaloge S, et al. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer 2012; 48:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/65\">",
"      Chamberlain MC. Bevacizumab plus irinotecan in recurrent glioblastoma. J Clin Oncol 2008; 26:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/66\">",
"      Clark AJ, Butowski NA, Chang SM, et al. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 2011; 114:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/67\">",
"      Erinjeri JP, Fong AJ, Kemeny NE, et al. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 2011; 117:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/68\">",
"      Zawacki WJ, Walker TG, DeVasher E, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol 2009; 20:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/69\">",
"      Spigel DR, Hainsworth JD, Yardley DA, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010; 28:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/70\">",
"      Gore E, Currey A, Choong N. Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. J Thorac Oncol 2009; 4:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/71\">",
"      Goodgame B, Veeramachaneni N, Patterson A, Govindan R. Tracheo-esophageal fistula with bevacizumab after mediastinal radiation. J Thorac Oncol 2008; 3:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/72\">",
"      Feyerabend S, Schilling D, Wicke C, Stenzl A. Toxic dermatolysis, tissue necrosis and impaired wound healing due to sunitinib treatment leading to forefoot amputation. Urol Int 2009; 82:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/73\">",
"      Chapin BF, Delacroix SE Jr, Culp SH, et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 2011; 60:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/74\">",
"      Jonasch E, Wood CG, Matin SF, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:4076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/75\">",
"      Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011; 22:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/76\">",
"      Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012; 104:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/77\">",
"      Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 2007; 105:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/78\">",
"      Mir O, Mouthon L, Alexandre J, et al. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst 2007; 99:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/79\">",
"      Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/80\">",
"      Ganapathi AM, Westmoreland T, Tyler D, Mantyh CR. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. J Am Coll Surg 2012; 214:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/81\">",
"      Kabbinavar FF, Flynn PJ, Kozloff M, et al. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer 2012; 48:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/82\">",
"      Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009; 10:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/83\">",
"      Schellhaas E, Loddenkemper C, Schmittel A, et al. Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Invest New Drugs 2009; 27:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/84\">",
"      Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/85\">",
"      B&egrave;ge T, Lelong B, Viret F, et al. Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients. Ann Surg Oncol 2009; 16:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/86\">",
"      Ley EJ, Vukasin P, Kaiser AM, et al. Delayed rectovaginal fistula: a potential complication of bevacizumab (avastin). Dis Colon Rectum 2007; 50:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/87\">",
"      Liu SV, Gollard R, Iqbal S. Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab. J Clin Pharm Ther 2012; 37:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/88\">",
"      Tol J, Cats A, Mol L, et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 2008; 26:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/89\">",
"      Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50 Suppl 1:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/90\">",
"      Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009; 75:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/91\">",
"      Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/92\">",
"      Richardson DL, Backes FJ, Hurt JD, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol 2010; 118:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/93\">",
"      Aghajanian C. The role of bevacizumab in ovarian cancer--an evolving story. Gynecol Oncol 2006; 102:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/94\">",
"      Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/95\">",
"      Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008; 110:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/96\">",
"      Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007; 107:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/97\">",
"      Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/98\">",
"      Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/99\">",
"      Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/100\">",
"      Walraven M, Witteveen PO, Lolkema MP, et al. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2011; 14:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/101\">",
"      Flaig TW, Kim FJ, La Rosa FG, et al. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs 2009; 27:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/102\">",
"      Hur H, Park AR, Jee SB, et al. Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. World J Gastroenterol 2008; 14:6096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/103\">",
"      Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 2008; 26:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/104\">",
"      Park SG, Chung CH, Park CY. Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report. Tumori 2011; 97:794.",
"     </a>",
"    </li>",
"    <li>",
"     Campbell NP, Wroblewski K, Maki RG, et al. Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST) (abstract). Data presented at the 2011 ASCO GI Cancers Symposium, January 20-22, San Francisco, CA. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=103&amp;abstractID=70751 (Accessed on March 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/106\">",
"      Diaz JP, Tew WP, Zivanovic O, et al. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecol Oncol 2010; 116:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/107\">",
"      Shinagare AB, Howard SA, Krajewski KM, et al. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol 2012; 199:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/108\">",
"      Badgwell BD, Camp ER, Feig B, et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 2008; 19:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/109\">",
"      Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.",
"     </a>",
"    </li>",
"    <li>",
"     Motzer RJ ND, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. J Clin Oncol 2012; 30s (suppl; abstr 4501).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/111\">",
"      Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008; 26:4037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/112\">",
"      Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/113\">",
"      Nicolatou-Galitis O, Migkou M, Psyrri A, et al. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/114\">",
"      Pakosch D, Papadimas D, Munding J, et al. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/115\">",
"      Bevacizumab, sunitinib: osteonecrosis of the jaw. Prescrire Int 2011; 20:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/116\">",
"      Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat 2010; 122:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/117\">",
"      Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008; 19:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/118\">",
"      Koch FP, Walter C, Hansen T, et al. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 2011; 15:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/119\">",
"      Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/120\">",
"      Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009; 27:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/121\">",
"      Beuselinck B, Wolter P, Karadimou A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012; 107:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/122\">",
"      Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76:209.",
"     </a>",
"    </li>",
"    <li>",
"     Bozas G, Allgar V, Greenwood G, MAraveyas A. Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid (absgrtact e15116). J Clin Oncol 2011; 29(suppl):. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=82466 (Accessed on January 29, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/124\">",
"      Sclafani F, Giuseppe G, Mezynksi J, et al. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer. J Clin Oncol 2012; 30:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/125\">",
"      Lou E, Turner S, Sumrall A, et al. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol 2011; 29:e739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/126\">",
"      Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/127\">",
"      Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/128\">",
"      Mart&iacute;n G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007; 25:3559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/129\">",
"      Govindarajan R, Adusumilli J, Baxter DL, et al. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006; 24:e48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/130\">",
"      Chelis L, Souftas V, Amarantidis K, et al. Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC Cancer 2012; 12:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/131\">",
"      Dogan E, Aksoy S, Arslan C, et al. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol 2010; 27:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/132\">",
"      Kapiteijn E, Brand A, Kroep J, Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007; 18:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/133\">",
"      Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006; 63:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/134\">",
"      Seet RC, Rabinstein AA. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM 2012; 105:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/135\">",
"      Choi MK, Hong JY, Jang JH, Lim HY. TTP-HUS associated with sunitinib. Cancer Res Treat 2008; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/136\">",
"      Talebi TN, Stefanovic A, Merchan J, et al. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome. Am J Ther 2012; 19:e143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/137\">",
"      Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer 2008; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/138\">",
"      Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/139\">",
"      Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/140\">",
"      Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/141\">",
"      Feldt S, Sch&uuml;ssel K, Quinzler R, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer 2012; 48:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/142\">",
"      Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/143\">",
"      Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92:3531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/144\">",
"      Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008; 69:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/145\">",
"      Faris JE, Moore AF, Daniels GH. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 2007; 17:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/146\">",
"      Sakurai K, Fukazawa H, Arihara Z, Yoshida K. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. Tohoku J Exp Med 2010; 222:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/147\">",
"      Alexandrescu DT, Popoveniuc G, Farzanmehr H, et al. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies. Thyroid 2008; 18:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/148\">",
"      Tamaskar I, Bukowski R, Elson P, et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 2008; 19:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/149\">",
"      Miyake H, Kurahashi T, Yamanaka K, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 2010; 28:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/150\">",
"      Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27:3312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/151\">",
"      Robinson SI, Hobday TJ, Sathananthan A, et al. Can sorafenib cause hypothyroidism? J Chemother 2007; 19:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/152\">",
"      Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs 2012; 30:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/153\">",
"      Figlin RA, de Souza P, McDermott D, et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009; 115:3651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/154\">",
"      Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/155\">",
"      Heath EI, Blumenschein GR Jr, Cohen RB, et al. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol 2011; 68:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/156\">",
"      van Erp NP, Mathijssen RH, van der Veldt AA, et al. Myelosuppression by sunitinib is flt-3 genotype dependent. Br J Cancer 2010; 103:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/157\">",
"      van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009; 27:4406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/158\">",
"      Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in Patients With Advanced Prostate Cancer:. J Clin Oncol.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/159\">",
"      Boers-Doets CB, Epstein JB, Raber-Durlacher JE, et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 2012; 17:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/160\">",
"      Lee JS, Hirsh V, Park K, et al. Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/161\">",
"      Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/162\">",
"      Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/163\">",
"      Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/164\">",
"      Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/165\">",
"      Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/166\">",
"      Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/167\">",
"      Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/168\">",
"      Poprach A, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012; 23:3137.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved manufacturer's package insert for sorafenib available online at file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0#section-2 (Accessed on January 31, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/170\">",
"      Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/171\">",
"      Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/172\">",
"      Billemont B, Medioni J, Taillade L, et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008; 99:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/173\">",
"      Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011; 17:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/174\">",
"      Mailliez A, Baldini C, Van JT, et al. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer 2010; 103:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/175\">",
"      Ramiscal JA, Jatoi A. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients. Acta Oncol 2011; 50:578.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.medscape.com/viewarticle/545083 (Accessed on January 31, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/177\">",
"      Ramiscal JA, Jatoi A. Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance. Curr Oncol Rep 2012; 14:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/178\">",
"      Diamantopoulos II, Jones NS. The investigation of nasal septal perforations and ulcers. J Laryngol Otol 2001; 115:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/179\">",
"      Watson D, Barkdull G. Surgical management of the septal perforation. Otolaryngol Clin North Am 2009; 42:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/180\">",
"      Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. Oncologist 2006; 11:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/181\">",
"      Ruiz N, Fernandez-Martos C, Romero I, et al. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol 2007; 25:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/182\">",
"      Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/183\">",
"      Antoun S, Birdsell L, Sawyer MB, et al. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 2010; 28:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/184\">",
"      Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012; 7:e37563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/185\">",
"      Poterucha T, Burnette B, Jatoi A. A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med Oncol 2012; 29:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/54/43882/abstract/186\">",
"      Parsons HA, Tsimberidou AM, Pontikos M, et al. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer 2012; 64:206.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86366 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43882=[""].join("\n");
var outline_f42_54_43882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1651229780\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1651224889\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H89432012\">",
"      RISK OF FATALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1651224896\">",
"      CLASS EFFECTS OF VEGF INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651225341\">",
"      Proteinuria/nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651225348\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651225355\">",
"      Other renal problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651225362\">",
"      Alterations in red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227378\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227385\">",
"      - Bevacizumab and aflibercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227392\">",
"      - Antiangiogenic TKIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227399\">",
"      - Special categories of bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1651227407\">",
"      Intracranial bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1651227415\">",
"      Pulmonary hemorrhage and cavitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227422\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227429\">",
"      Delayed wound healing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227437\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H91044850\">",
"      Hepatic metastasectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H91044857\">",
"      Recurrent glioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H91044864\">",
"      Portacath placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H91044871\">",
"      Tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227444\">",
"      - Antiangiogenic TKIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227451\">",
"      Intestinal perforation/fistula formation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227458\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H435713276\">",
"      Diseases other than ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H435713269\">",
"      Ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H687211801\">",
"      - Aflibercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227465\">",
"      - Antiangiogenic TKIs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651227472\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1557945051\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1557944968\">",
"      Dysphonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651228672\">",
"      Osteonecrosis of the jaw",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H609118754\">",
"      - Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651228679\">",
"      Reversible posterior leukoencephalopathy and brain capillary leak syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H609118768\">",
"      - Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651228686\">",
"      Microangiopathic hemolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229236\">",
"      CLASS EFFECTS OF VEGF RECEPTOR TKIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229244\">",
"      Thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229251\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229258\">",
"      Myelosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229272\">",
"      Stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229279\">",
"      Gastrointestinal toxicities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H609118804\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229286\">",
"      Cutaneous toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H609119004\">",
"      - Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1557944336\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1557944363\">",
"      - Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1557944370\">",
"      - Ponatinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1557944377\">",
"      - Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1557944384\">",
"      - Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184151441\">",
"      - Monitoring and mangement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229307\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229315\">",
"      - Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229323\">",
"      - Glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H609119062\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229330\">",
"      AGENT SPECIFIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229338\">",
"      Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229346\">",
"      - Nasal septal perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H609119069\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1557944583\">",
"      Sorafenib and muscle wasting/sarcopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1651229780\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/86366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/86366|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/50/22316\" title=\"table 1\">",
"      Medical conditions with RPLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/21/25948\" title=\"table 2\">",
"      Hematologic toxicity grades NCI CTCAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/45/7900\" title=\"table 3\">",
"      Cutan react multitarg TKI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/56/10123\" title=\"table 4\">",
"      Grading HFSR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 5\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/9/33947\" title=\"table 6\">",
"      Etiologies of nasal septal perforation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=related_link\">",
"      Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/41/1690?source=related_link\">",
"      Approach to the adult with epistaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23288?source=related_link\">",
"      Chemotherapy and immunotherapy for medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=related_link\">",
"      Enteral stents for the management of malignant colorectal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16072?source=related_link\">",
"      Etiologies of nasal symptoms: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41770?source=related_link\">",
"      Evaluation of the adult with abdominal pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36328?source=related_link\">",
"      Management of recurrent malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/21/37209?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/49/42777?source=related_link\">",
"      Microalbuminuria in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/33/39449?source=related_link\">",
"      Microalbuminuria in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29558?source=related_link\">",
"      Overview of massive hemoptysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/51/43830?source=related_link\">",
"      Overview of thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39898?source=related_link\">",
"      Systemic treatment for advanced hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11832?source=related_link\">",
"      The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/58/34730?source=related_link\">",
"      Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5177?source=related_link\">",
"      Wound healing and risk factors for non-healing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_54_43883="Causes neonatal death";
var content_f42_54_43883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Leading causes of neonatal death in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neonatal deaths",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percentage of neonatal deaths",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disorders related to prematurity and low birth weight",
"       </td>",
"       <td>",
"        4318",
"       </td>",
"       <td>",
"        23.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital malformations, chromosomal abnormalities",
"       </td>",
"       <td>",
"        4144",
"       </td>",
"       <td>",
"        22.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal complications",
"       </td>",
"       <td>",
"        1394",
"       </td>",
"       <td>",
"        7.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placenta, cord, and membrane complications",
"       </td>",
"       <td>",
"        1049",
"       </td>",
"       <td>",
"        5.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory distress",
"       </td>",
"       <td>",
"        929",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial sepsis",
"       </td>",
"       <td>",
"        737",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrauterine hypoxia and birth asphyxia",
"       </td>",
"       <td>",
"        589",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal hemorrhage",
"       </td>",
"       <td>",
"        563",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atelectasis",
"       </td>",
"       <td>",
"        483",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrotizing enterocolitis",
"       </td>",
"       <td>",
"        313",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Neonatal deaths: death within 28 days of birth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: the Centers for Disease Control and Prevention, 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43883=[""].join("\n");
var outline_f42_54_43883=null;
var title_f42_54_43884="Chemoprophylaxis N meningitidis";
var content_f42_54_43884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial chemoprophylaxis regimens for meningococcal disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Age group",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Rifampin (oral)",
"      </td>",
"      <td>",
"       Children &lt;1 month",
"      </td>",
"      <td>",
"       5 mg/kg every 12 hours",
"      </td>",
"      <td>",
"       Two days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Children &ge;1 month",
"      </td>",
"      <td>",
"       10 mg/kg every 12 hours",
"      </td>",
"      <td>",
"       Two days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adults",
"      </td>",
"      <td>",
"       600 mg every 12 hours",
"      </td>",
"      <td>",
"       Two days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ciprofloxacin (oral)",
"      </td>",
"      <td>",
"       Adults",
"      </td>",
"      <td>",
"       500 mg",
"      </td>",
"      <td>",
"       Single oral dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Ceftriaxone (intramuscular)",
"      </td>",
"      <td>",
"       Children &lt;15 years",
"      </td>",
"      <td>",
"       125 mg",
"      </td>",
"      <td>",
"       Single IM dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Older children and adults",
"      </td>",
"      <td>",
"       250 mg",
"      </td>",
"      <td>",
"       Single IM dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       Azithromycin",
"      </td>",
"      <td>",
"       Children &lt;15 years",
"      </td>",
"      <td>",
"       10 mg/kg",
"      </td>",
"      <td>",
"       Single oral dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Children &gt;15 years",
"      </td>",
"      <td>",
"       500 mg",
"      </td>",
"      <td>",
"       Single oral dose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"4\" rowspan=\"1\">",
"       Notes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Rifampin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"4\" rowspan=\"1\">",
"       Not recommended for pregnant women",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"4\" rowspan=\"1\">",
"       May reduce reliability of oral contraceptives",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"4\" rowspan=\"1\">",
"       Causes reddish-orange discoloration of urine, tears, and other body fluids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Ciprofloxacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"4\" rowspan=\"1\">",
"       Not recommended for individuals less than 18 years of age or in pregnant or lactating women; however, can be used in children if no other alternative is available. Not recommended in selected counties in North Dakota and Minnesota.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Azithromycin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"4\" rowspan=\"1\">",
"       Not routinely recommended, but may be used in regions with ciprofloxacin-resistant isolates.*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" colspan=\"4\" rowspan=\"1\">",
"       Azithromycin has been shown in one study to be equivalent to rifampin.&bull;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IM: intramuscular.",
"     <br>",
"      * Emergence of fluoroquinolone-resistant Neisseria meningitidis - Minnesota and North Dakota, 2007-2008. MMWR Morb Mortal Wkly Rep 2008; 57(07):173.",
"      <br>",
"       &bull; Girgis, N, Sultan, Y, Frank, RW Jr, et al. Azithromycin compares with rifampin for eradication of nasopharyngeal colonization by Neisseria meningitidis. Pediatr Infect Dis J 1998; 17:816.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bilukha, OO, Rosenstein, N.Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb MortalWkly Rep 2005; 54(RR-7):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43884=[""].join("\n");
var outline_f42_54_43884=null;
var title_f42_54_43885="MRS at rest in HF";
var content_f42_54_43885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impaired muscle metabolism in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 383px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance spectropscopy (MRS) performed at rest in normal controls and patients with heart failure (HF). The inorganic phosphate (Pi), phosphocreatine (PCr), and three adenosine triphosphate (ATP) peaks are identified; the pH is determined by the chemical shift between the PCr and Pi peak. Using the observed values, the concentrations of PCr and Pi and the Pi/PCr ratio of the areas under the Pi and PCr peaks are calculated; this ratio provides an estimation of the high energy phosphate supply available for utilization. An increase in the Pi/PCr ratio, as seen in HF, suggests a reduction in energy supply and is an useful indicator of the rate of energy utilization during exercise.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Massie, B, Conway, M, Yonge, R, et al, Am J Cardiol 1987; 60:309.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43885=[""].join("\n");
var outline_f42_54_43885=null;
var title_f42_54_43886="Rolando fracture of thumb metacarpal";
var content_f42_54_43886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fracture of the 1st metacarpal base: Type II (Rolando)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain radiograph shows a&nbsp;comminuted, intraarticular fracture of the thumb metacarpal. The eponym for this injury is&nbsp; Rolando's fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E. Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43886=[""].join("\n");
var outline_f42_54_43886=null;
var title_f42_54_43887="Hamartoma CT";
var content_f42_54_43887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary hamartoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Benign pattern of calcification in a solitary pulmonary nodule with characteristic popcorn configuration suggestive of a hamartoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_54_43887=[""].join("\n");
var outline_f42_54_43887=null;
